

DESCRIPTION

C17-ALKANEDIYL AND ALKENEDIYL DERIVATIVES OF OLEANOLIC ACID AND METHODS OF USE THEREOF

BACKGROUND OF THE INVENTION

5 This application claims the benefit of both United States Provisional Patent Application No. 61/699,122, filed on September 10, 2012 and United States Provisional Patent Application No. 61/780,540, filed on March 13, 2013, the entirety of both are incorporated herein by reference.

 Pursuant to 37 C.F.R. 1.821(c), a sequence listing is submitted herewith as an ASCII
10 compliant text file named "REATP0074US_SequenceListing_ST25.txt", created on September 5, 2013 and having a size of ~1 KB. The content of the aforementioned file is hereby incorporated by reference in its entirety.

I. Field of the Invention

 The present invention relates generally to the fields of biology and medicine. More
15 particularly, it concerns compounds, compositions and methods for the treatment and prevention of diseases such as those associated with oxidative stress and inflammation.

II. Description of Related Art

 The anti-inflammatory and anti-proliferative activity of the naturally occurring triterpenoid, oleanolic acid, has been improved by chemical modifications. For example, 2-
20 cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO) and related compounds have been developed (Honda *et al.*, 1997; Honda *et al.*, 1998; Honda *et al.*, 1999; Honda *et al.*, 2000a; Honda *et al.*, 2000b; Honda, *et al.*, 2002; Suh *et al.* 1998; Suh *et al.*, 1999; Place *et al.*, 2003; Liby *et al.*, 2005; and U.S. Patents 8,129,429; 7,915,402; 8,124,799; 8,071,632; 8,338,618; and 7,943,778). The methyl ester, bardoxolone methyl (CDDO-Me), has been
25 evaluated clinically for the treatment of cancer and chronic kidney disease (Pergola *et al.*, 2011; Hong *et al.*, 2012).


 Synthetic triterpenoid analogs of oleanolic acid have also been shown to be inhibitors of cellular inflammatory processes, such as the induction by IFN- γ of inducible nitric oxide synthase (iNOS) and of COX-2 in mouse macrophages. See Honda *et al.* (2000a); Honda *et al.* (2000b), and Honda *et al.* (2002). Synthetic derivatives of another triterpenoid, betulinic
30 acid, have also been shown to inhibit cellular inflammatory processes, although these

compounds have been less extensively characterized (Honda *et al.*, 2006). The pharmacology of these synthetic triterpenoid molecules is complex. Compounds derived from oleanolic acid have been shown to affect the function of multiple protein targets and thereby modulate the activity of several important cellular signaling pathways related to oxidative stress, cell cycle control, and inflammation (*e.g.*, Dinkova-Kostova *et al.*, 2005; Ahmad *et al.*, 2006; Ahmad *et al.*, 2008; Liby *et al.*, 2007a). Derivatives of betulinic acid, though they have shown comparable anti-inflammatory properties, also appear to have significant differences in their pharmacology compared to OA-derived compounds (Liby *et al.*, 2007b). Given that the biological activity profiles of known triterpenoid derivatives vary, and in view of the wide variety of diseases that may be treated or prevented with compounds having potent antioxidant and anti-inflammatory effects, and the high degree of unmet medical need represented within this variety of diseases, it is desirable to synthesize new compounds with diverse structures that may have improved biological activity profiles for the treatment of one or more indications.

SUMMARY OF THE INVENTION

The present disclosure provides novel synthetic triterpenoid derivatives, with anti-inflammatory and/or antioxidant properties, pharmaceutical compositions, and methods for their manufacture, and methods for their use.

In one aspect, there are provided compounds of the formula:



wherein:

Y is a covalent bond, $-\text{CH}_2-$, $-\text{C}(\text{O})-$, $-\text{O}-$, or $-\text{NH}-$;

R_1 and R_2 are each independently $-H$, $-OH$, methyl, or as defined below; and

R_3 is:

hydrogen, hydroxy, halo, amino, $-NHOH$, or mercapto;

alkyl_(C≤8), alkenyl_(C≤8), alkynyl_(C≤8), aryl_(C≤8), aralkyl_(C≤8), heteroaryl_(C≤8),

5 heterocycloalkyl_(C≤8), acyl_(C≤8), alkoxy_(C≤8), alkenyloxy_(C≤8),

aryloxy_(C≤8), aralkoxy_(C≤8), heteroaryloxy_(C≤8), acyloxy_(C≤8),

heterocycloalkoxy_(C≤8), alkylamino_(C≤8), dialkylamino_(C≤8),

alkenylamino_(C≤8), alkoxyamino_(C≤8), arylamino_(C≤8), aralkylamino_(C≤8),

heteroarylamino_(C≤8), heterocycloalkylamino_(C≤8),

10 alkylsulfonylamino_(C≤8), amido_(C≤8), $-NH-$ amido_(C≤8), or a substituted

version of any of these groups;

R_3 and R_1 , taken together, are $-O-$, $-NR_a-$ or a covalent bond between Y and carbon atom 13, wherein R_a is hydrogen or alkyl_(C≤4); or


R_3 and R_2 , taken together, are $-O-$, $-NR_a-$ or a covalent bond between Y and carbon atom 14, wherein R_a is hydrogen or alkyl_(C≤4);

15

carbon atom 14, wherein R_a is hydrogen or alkyl_(C≤4);

or a pharmaceutically acceptable salt thereof.

In some embodiments, the compounds are further defined as:



wherein:

20 Y is $-CH_2-$, $-C(O)-$, $-O-$, or $-NH-$;

R_1 and R_2 are each independently $-H$, $-OH$, methyl, or as defined below; and

R_3 is:

hydrogen, hydroxy, halo, amino, $-\text{NHOH}$, or mercapto;


alkyl_(C≤8), alkenyl_(C≤8), alkynyl_(C≤8), aryl_(C≤8), aralkyl_(C≤8), heteroaryl_(C≤8),
 heterocycloalkyl_(C≤8), acyl_(C≤8), alkoxy_(C≤8), alkenyloxy_(C≤8),
 aryloxy_(C≤8), aralkoxy_(C≤8), heteroaryloxy_(C≤8), acyloxy_(C≤8),
 heterocycloalkoxy_(C≤8), alkylamino_(C≤8), dialkylamino_(C≤8),
 alkenylamino_(C≤8), alkoxyamino_(C≤8), arylamino_(C≤8), aralkylamino_(C≤8),
 heteroarylamino_(C≤8), heterocycloalkylamino_(C≤8),
 alkylsulfonylamino_(C≤8), amido_(C≤8), $-\text{NH-amido}_{(C≤8)}$, or a substituted
 version of any of these groups;

R_3 and R_1 , taken together, are $-\text{O}-$, $-\text{NR}_a-$ or a covalent bond between Y and
 carbon atom 13, wherein R_a is hydrogen or alkyl_(C≤4); or

R_3 and R_2 , taken together, are $-\text{O}-$, $-\text{NR}_a-$ or a covalent bond between Y and
 carbon atom 14, wherein R_a is hydrogen or alkyl_(C≤4);

or a pharmaceutically acceptable salt thereof.

In some embodiments, the compounds are further defined as:



wherein:

Y is a covalent bond, $-\text{CH}_2-$, $-\text{C}(\text{O})-$, $-\text{O}-$, or $-\text{NH}-$; and


R_3 is:

hydrogen, hydroxy, halo, amino, $-\text{NHOH}$, or mercapto; or

alkyl_(C≤8), alkenyl_(C≤8), alkynyl_(C≤8), aryl_(C≤8), aralkyl_(C≤8), heteroaryl_(C≤8),
 heterocycloalkyl_(C≤8), acyl_(C≤8), alkoxy_(C≤8), alkenyloxy_(C≤8),

- aryloxy_(C≤8), aralkoxy_(C≤8), heteroaryloxy_(C≤8), acyloxy_(C≤8),
 heterocycloalkoxy_(C≤8), alkylamino_(C≤8), dialkylamino_(C≤8),
 alkenylamino_(C≤8), alkoxyamino_(C≤8), arylamino_(C≤8), aralkylamino_(C≤8),
 heteroarylamino_(C≤8), heterocycloalkylamino_(C≤8),
 5 alkylsulfonylamino_(C≤8), amido_(C≤8), -NH-amido_(C≤8), or a substituted
 version of any of these groups;
 or a pharmaceutically acceptable salt thereof.

In some embodiments, the compounds are further defined as:



10 wherein:

Y is -CH₂-, -C(O)-, -O-, or -NH-; and


R₃ is:


- hydrogen, hydroxy, halo, amino, -NHOH, or mercapto; or
 alkyl_(C≤8), alkenyl_(C≤8), alkynyl_(C≤8), aryl_(C≤8), aralkyl_(C≤8), heteroaryl_(C≤8),
 15 heterocycloalkyl_(C≤8), acyl_(C≤8), alkoxy_(C≤8), alkenyloxy_(C≤8),
 aryloxy_(C≤8), aralkoxy_(C≤8), heteroaryloxy_(C≤8), acyloxy_(C≤8),
 heterocycloalkoxy_(C≤8), alkylamino_(C≤8), dialkylamino_(C≤8),
 alkenylamino_(C≤8), alkoxyamino_(C≤8), arylamino_(C≤8), aralkylamino_(C≤8),
 heteroarylamino_(C≤8), heterocycloalkylamino_(C≤8),
 20 alkylsulfonylamino_(C≤8), amido_(C≤8), -NH-amido_(C≤8), or a substituted
 version of any of these groups;
 or a pharmaceutically acceptable salt thereof.


In some embodiments, the bond between carbon atoms a and b is a single bond. In some embodiments, the bond between carbon atoms a and b is a double bond. In some embodiments, Y is a covalent bond. In some embodiments, Y is $-\text{CH}_2-$. In some embodiments, Y is $-\text{C}(\text{O})-$. In some embodiments, Y is $-\text{O}-$. In some embodiments, R_1 is $-\text{H}$. In some embodiments, R_2 is methyl.


In some embodiments, R_3 is $-\text{H}$. In some embodiments, R_3 is $-\text{OH}$. In some embodiments, R_3 is amino. In some embodiments, R_3 is $\text{alkyl}_{(\text{C}\leq 8)}$, for example methyl. In some embodiments, R_3 is heterocycloalkyl $_{(\text{C}\leq 8)}$, for example, morpholinyl, pyrrolidinyl, azetidinyl or piperazinyl. In some embodiments, R_3 is substituted heterocycloalkyl $_{(\text{C}\leq 8)}$, for example, hydroxypyrrolidinyl, difluoropyrrolidinyl, hydroxypiperidinyl, or *N*-Boc-piperazinyl. In some embodiments, R_3 is acyl $_{(\text{C}\leq 8)}$, for example, acetyl. In some embodiments, R_3 is substituted acyl $_{(\text{C}\leq 8)}$, for example, ethylaminocarbonyl. In some embodiments, R_3 is alkoxy $_{(\text{C}\leq 8)}$, for example, methoxy, ethoxy, isopropoxy, *tert*-butoxy, or $-\text{O}-\text{cyclohexyl}$. In some embodiments, R_3 is aryloxy $_{(\text{C}\leq 8)}$, for example, $-\text{O}-\text{phenyl}$. In some embodiments, R_3 is aralkoxy $_{(\text{C}\leq 8)}$, for example, benzyloxy. In some embodiments, R_3 is substituted acyloxy $_{(\text{C}\leq 8)}$, for example, $-\text{OC}(\text{O})\text{NHCH}_2\text{CH}_3$. In some embodiments, R_3 is heterocycloalkoxy $_{(\text{C}\leq 8)}$, for example, $-\text{O}-\text{piperidinyl}$ or *N*-Boc-piperidinyl. In some embodiments, R_3 is alkylamino $_{(\text{C}\leq 8)}$, for example, methylamino, ethylamino, isopropylamino, *tert*-butylamino or cyclohexylamino. In some embodiments, R_3 is substituted alkylamino $_{(\text{C}\leq 8)}$, for example, 2,2,2-trifluoroethylamino, $-\text{NHCH}_2\text{C}(\text{O})\text{OCH}_3$ or $-\text{NHCH}_2\text{C}(\text{O})\text{OH}$. In some embodiments, R_3 is dialkylamino $_{(\text{C}\leq 8)}$, for example, dimethylamino. In some embodiments, R_3 is alkoxyamino $_{(\text{C}\leq 8)}$, for example, methoxyamino. In some embodiments, R_3 is arylamino $_{(\text{C}\leq 8)}$, for example, phenylamino. In some embodiments, R_3 is aralkylamino $_{(\text{C}\leq 8)}$, for example, benzylamino. In some embodiments, R_3 is heteroaryl $_{(\text{C}\leq 8)}$, for example, pyridinylamino. In some embodiments, R_3 is heterocycloalkylamino $_{(\text{C}\leq 8)}$, for example, oxetanyl $_{(\text{C}\leq 8)}$ amino. In some embodiments, R_3 is $-\text{NH}-\text{amido}_{(\text{C}\leq 8)}$, for example, $-\text{NHNHC}(\text{O})\text{CH}_3$.

In some embodiments, the compounds are selected from the groups comprising:










or a pharmaceutically acceptable salts of any of these formulas.

In one aspect, there are provided compounds of the formula:



wherein:

n is 1 to 6;

R_1 and R_2 are each independently $-H$, $-OH$, methyl, or as defined below; and

R_3 is:

10

amino or $-NHOH$; or

N -heteroaryl_(C≤8), N -heterocycloalkyl_(C≤8), alkylamino_(C≤8), dialkylamino_(C≤8),
alkenylamino_(C≤8), alkoxyamino_(C≤8), arylamino_(C≤8), aralkylamino_(C≤8),
heteroarylamino_(C≤8), heterocycloalkylamino_(C≤8),


alkylsulfonylamino_(C≤8), amido_(C≤8), -NH-amido_(C≤8), or a substituted version of any of these groups;

R₃ and R₁, taken together, are -NR_a-, wherein R_a is hydrogen or alkyl_(C≤4); or

R₃ and R₂, taken together, are -NR_a-, wherein R_a is hydrogen or alkyl_(C≤4); or

5 or a pharmaceutically acceptable salt thereof.

In some embodiments, the compounds are further defined as:



wherein:

n is 1 to 6; and

10 R₃ is:

amino or -NHOH; or

N-heteroaryl_(C≤8), *N*-heterocycloalkyl_(C≤8), alkylamino_(C≤8), dialkylamino_(C≤8),

alkenylamino_(C≤8), alkoxyamino_(C≤8), arylamino_(C≤8), aralkylamino_(C≤8),

heteroarylamino_(C≤8), heterocycloalkylamino_(C≤8),

15 alkylsulfonylamino_(C≤8), amido_(C≤8), -NH-amido_(C≤8), or a substituted version of any of these groups;


or a pharmaceutically acceptable salt thereof.

In some embodiments, n is 1. In other embodiments, n is 2. In still other embodiments, n is 3.

20 In some embodiments, R₁ is -H. In some embodiments, R₂ is methyl.

In some embodiments, R₃ is *N*-heteroaryl_(C≤8), for example, imidazolyl. In some embodiments, R₃ is *N*-heterocycloalkyl_(C≤8), for example, morpholinyl or pyrrolidinyl. In some embodiments, R₃ is alkylamino_(C≤8), for example, ethylamino.

In some embodiments, the compounds are selected from the groups comprising:



5 or a pharmaceutically acceptable salt thereof.

In some aspects, there are provided pharmaceutical compositions comprising one or more of the above compounds and an excipient. In other aspects there are provided methods of treating and/or preventing a disease or a disorder in patients in need thereof, comprising administering to such patients one or more of the above compounds in an amount sufficient
10 to treat and/or prevent the disease or disorder.

Other objects, features and advantages of the present disclosure will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating specific embodiments of the invention, are given by way of illustration only, since various changes and modifications
15 within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description. Note that simply because a particular compound is ascribed to one particular generic formula doesn't mean that it cannot also belong to another generic formula.

DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

Disclosed herein are new compounds and compositions with antioxidant and/or anti-inflammatory properties, methods for their manufacture, and methods for their use, including for the treatment and/or prevention of disease.

5 I. Definitions

When used in the context of a chemical group: “hydrogen” means $-H$; “hydroxy” means $-OH$; “oxo” means $=O$; “carbonyl” means $-C(=O)-$; “carboxy” means $-C(=O)OH$ (also written as $-COOH$ or $-CO_2H$); “halo” means independently $-F$, $-Cl$, $-Br$ or $-I$; “amino” means $-NH_2$; “hydroxyamino” means $-NHOH$; “nitro” means $-NO_2$; imino means
 10 $=NH$; “cyano” means $-CN$; “isocyanate” means $-N=C=O$; “azido” means $-N_3$; in a monovalent context “phosphate” means $-OP(O)(OH)_2$ or a deprotonated form thereof; in a divalent context “phosphate” means $-OP(O)(OH)O-$ or a deprotonated form thereof; “mercapto” means $-SH$; and “thio” means $=S$; “sulfonyl” means $-S(O)_2-$; and “sulfinyl” means $-S(O)-$.

15 In the context of chemical formulas, the symbol “—” means a single bond, “=” means a double bond, and “≡” means triple bond. The symbol “----” represents an optional bond, which if present is either single or double. The symbol “====” represents a single bond or a


double bond. Thus, for example, the formula  includes , , ,  and




. And it is understood that no one such ring atom forms part of more than one double bond.
 20 Furthermore, it is noted that the covalent bond symbol “—”, when connecting one or two stereogenic atoms, does not indicate any preferred stereochemistry. Instead, it covers all stereoisomers as well as mixtures thereof. The symbol “”, when drawn perpendicularly across a bond (e.g., -CH₃ for methyl) indicates a point of attachment of the group. It is noted that the point of attachment is typically only identified in this manner for larger groups
 25 in order to assist the reader in unambiguously identifying a point of attachment. The symbol “” means a single bond where the group attached to the thick end of the wedge is “out of the page.” The symbol “” means a single bond where the group attached to the thick end of the wedge is “into the page”. The symbol “” means a single bond where the geometry around a double bond (e.g., either *E* or *Z*) is undefined. Both options, as well as
 30 combinations thereof are therefore intended. The bond orders described above are not

limiting when one of the atoms connected by the bond is a metal atom (M). In such cases, it is understood that the actual bonding may comprise significant multiple bonding and/or ionic character. Therefore, unless indicated otherwise, the formulas M–C, M=C, M----C, and M
 5 =====C, each refers to a bond of any and type and order between a metal atom and a carbon atom. Any undefined valency on an atom of a structure shown in this application implicitly represents a hydrogen atom bonded to that atom. A bold dot on a carbon atom indicates that the hydrogen attached to that carbon is oriented out of the plane of the paper.

When a group “R” is depicted as a “floating group” on a ring system, for example, in the formula:



10 then R may replace any hydrogen atom attached to any of the ring atoms, including a depicted, implied, or expressly defined hydrogen, so long as a stable structure is formed. When a group “R” is depicted as a “floating group” on a fused ring system, as for example in the formula:



15 then R may replace any hydrogen attached to any of the ring atoms of either of the fused rings unless specified otherwise. Replaceable hydrogens include depicted hydrogens (*e.g.*, the hydrogen attached to the nitrogen in the formula above), implied hydrogens (*e.g.*, a hydrogen of the formula above that is not shown but understood to be present), expressly
 20 defined hydrogens, and optional hydrogens whose presence depends on the identity of a ring atom (*e.g.*, a hydrogen attached to group X, when X equals –CH–), so long as a stable structure is formed. In the example depicted, R may reside on either the 5-membered or the 6-membered ring of the fused ring system. In the formula above, the subscript letter “y” immediately following the group “R” enclosed in parentheses, represents a numeric variable.
 25 Unless specified otherwise, this variable can be 0, 1, 2, or any integer greater than 2, only limited by the maximum number of replaceable hydrogen atoms of the ring or ring system.

For the groups and classes below, the following parenthetical subscripts further define the group/class as follows: “(C_n)” defines the exact number (n) of carbon atoms in the group/class. “(C_{≤n})” defines the maximum number (n) of carbon atoms that can be in the

group/class, with the minimum number as small as possible for the group in question, e.g., it is understood that the minimum number of carbon atoms in the group “alkenyl_(C≤8)” or the class “alkene_(C≤8)” is two. For example, “alkoxy_(C≤10)” designates those alkoxy groups having from 1 to 10 carbon atoms. (C_n-n') defines both the minimum (n) and maximum number (n') of carbon atoms in the group. Similarly, “alkyl_(C2-10)” designates those alkyl groups having from 2 to 10 carbon atoms.

The term “saturated” as used herein means the compound or group so modified has no carbon-carbon double and no carbon-carbon triple bonds, except as noted below. In the case of substituted versions of saturated groups, one or more carbon oxygen double bond or a carbon nitrogen double bond may be present. And when such a bond is present, then carbon-carbon double bonds that may occur as part of keto-enol tautomerism or imine/enamine tautomerism are not precluded.

The term “aliphatic” when used without the “substituted” modifier signifies that the compound/group so modified is an acyclic or cyclic, but non-aromatic hydrocarbon compound or group. In aliphatic compounds/groups, the carbon atoms can be joined together in straight chains, branched chains, or non-aromatic rings (alicyclic). Aliphatic compounds/groups can be saturated, that is joined by single bonds (alkanes/alkyl), or unsaturated, with one or more double bonds (alkenes/alkenyl) or with one or more triple bonds (alkynes/alkynyl).

The term “alkyl” when used without the “substituted” modifier refers to a monovalent saturated aliphatic group with a carbon atom as the point of attachment, a linear or branched, cyclo, cyclic or acyclic structure, and no atoms other than carbon and hydrogen. Thus, as used herein cycloalkyl is a subset of alkyl, with the carbon atom that forms the point of attachment also being a member of one or more non-aromatic ring structures wherein the cycloalkyl group consists of no atoms other than carbon and hydrogen. As used herein, the term does not preclude the presence of one or more alkyl groups (carbon number limitation permitting) attached to the ring or ring system. The groups —CH₃ (Me), —CH₂CH₃ (Et), —CH₂CH₂CH₃ (*n*-Pr or propyl), —CH(CH₃)₂ (*i*-Pr, ¹Pr or isopropyl), —CH(CH₂)₂ (cyclopropyl), —CH₂CH₂CH₂CH₃ (*n*-Bu), —CH(CH₃)CH₂CH₃ (*sec*-butyl), —CH₂CH(CH₃)₂ (isobutyl), —C(CH₃)₃ (*tert*-butyl, *t*-butyl, *t*-Bu or ¹Bu), —CH₂C(CH₃)₃ (*neo*-pentyl), cyclobutyl, cyclopentyl, cyclohexyl, and cyclohexylmethyl are non-limiting examples of alkyl groups. The term “alkanediyl” when used without the “substituted” modifier refers to a divalent saturated aliphatic group, with one or two saturated carbon atom(s) as the point(s) of

attachment, a linear or branched, cyclo, cyclic or acyclic structure, no carbon-carbon double or triple bonds, and no atoms other than carbon and hydrogen. The groups, $-\text{CH}_2-$ (methylene), $-\text{CH}_2\text{CH}_2-$, $-\text{CH}_2\text{C}(\text{CH}_3)_2\text{CH}_2-$, $-\text{CH}_2\text{CH}_2\text{CH}_2-$, and , are non-limiting examples of alkanediyl groups. The term “alkylidene” when used without the “substituted” modifier refers to the divalent group $=\text{CRR}'$ in which R and R' are independently hydrogen, alkyl, or R and R' are taken together to represent an alkanediyl having at least two carbon atoms. Non-limiting examples of alkylidene groups include: $=\text{CH}_2$, $=\text{CH}(\text{CH}_2\text{CH}_3)$, and $=\text{C}(\text{CH}_3)_2$. An “alkane” refers to the compound $\text{H}-\text{R}$, wherein R is alkyl as this term is defined above. When any of these terms is used with the “substituted” modifier one or more hydrogen atom has been independently replaced by $-\text{OH}$, $-\text{F}$, $-\text{Cl}$, $-\text{Br}$, $-\text{I}$, $-\text{NH}_2$, $-\text{NO}_2$, $-\text{CO}_2\text{H}$, $-\text{CO}_2\text{CH}_3$, $-\text{CN}$, $-\text{SH}$, $-\text{OCH}_3$, $-\text{OCH}_2\text{CH}_3$, $-\text{C}(\text{O})\text{CH}_3$, $-\text{NHCH}_3$, $-\text{NHCH}_2\text{CH}_3$, $-\text{N}(\text{CH}_3)_2$, $-\text{C}(\text{O})\text{NH}_2$, $-\text{OC}(\text{O})\text{CH}_3$, or $-\text{S}(\text{O})_2\text{NH}_2$. The following groups are non-limiting examples of substituted alkyl groups: $-\text{CH}_2\text{OH}$, $-\text{CH}_2\text{Cl}$, $-\text{CF}_3$, $-\text{CH}_2\text{CN}$, $-\text{CH}_2\text{C}(\text{O})\text{OH}$, $-\text{CH}_2\text{C}(\text{O})\text{OCH}_3$, $-\text{CH}_2\text{C}(\text{O})\text{NH}_2$, $-\text{CH}_2\text{C}(\text{O})\text{CH}_3$, $-\text{CH}_2\text{OCH}_3$, $-\text{CH}_2\text{OC}(\text{O})\text{CH}_3$, $-\text{CH}_2\text{NH}_2$, $-\text{CH}_2\text{N}(\text{CH}_3)_2$, and $-\text{CH}_2\text{CH}_2\text{Cl}$. The term “haloalkyl” is a subset of substituted alkyl, in which one or more hydrogen atoms has been substituted with a halo group and no other atoms aside from carbon, hydrogen and halogen are present. The group, $-\text{CH}_2\text{Cl}$ is a non-limiting example of a haloalkyl. The term “fluoroalkyl” is a subset of substituted alkyl, in which one or more hydrogen has been substituted with a fluoro group and no other atoms aside from carbon, hydrogen and fluorine are present. The groups, $-\text{CH}_2\text{F}$, $-\text{CF}_3$, and $-\text{CH}_2\text{CF}_3$ are non-limiting examples of fluoroalkyl groups.


The term “alkenyl” when used without the “substituted” modifier refers to an monovalent unsaturated aliphatic group with a carbon atom as the point of attachment, a linear or branched, cyclo, cyclic or acyclic structure, at least one nonaromatic carbon-carbon double bond, no carbon-carbon triple bonds, and no atoms other than carbon and hydrogen. Non-limiting examples of alkenyl groups include: $-\text{CH}=\text{CH}_2$ (vinyl), $-\text{CH}=\text{CHCH}_3$, $-\text{CH}=\text{CHCH}_2\text{CH}_3$, $-\text{CH}_2\text{CH}=\text{CH}_2$ (allyl), $-\text{CH}_2\text{CH}=\text{CHCH}_3$, and $-\text{CH}=\text{CHCH}=\text{CH}_2$. The term “alkenediyl” when used without the “substituted” modifier refers to a divalent unsaturated aliphatic group, with two carbon atoms as points of attachment, a linear or branched, cyclo, cyclic or acyclic structure, at least one nonaromatic carbon-carbon double bond, no carbon-carbon triple bonds, and no atoms other than carbon and hydrogen. The groups, $-\text{CH}=\text{CH}-$, $-\text{CH}=\text{C}(\text{CH}_3)\text{CH}_2-$, $-\text{CH}=\text{CHCH}_2-$, and , are non-limiting

examples of alkenediyl groups. It is noted that while the alkenediyl group is aliphatic, once connected at both ends, this group is not precluded from forming part of an aromatic structure. The terms “alkene” or “olefin” are synonymous and refer to a compound having the formula H-R, wherein R is alkenyl as this term is defined above. A “terminal alkene”
5 refers to an alkene having just one carbon-carbon double bond, wherein that bond forms a vinyl group at one end of the molecule. When any of these terms are used with the “substituted” modifier one or more hydrogen atom has been independently replaced by -OH, -F, -Cl, -Br, -I, -NH₂, -NO₂, -CO₂H, -CO₂CH₃, -CN, -SH, -OCH₃, -OCH₂CH₃, -C(O)CH₃, -NHCH₃, -NHCH₂CH₃, -N(CH₃)₂, -C(O)NH₂, -OC(O)CH₃, or -S(O)₂NH₂.
10 The groups, -CH=CHF, -CH=CHCl and -CH=CHBr, are non-limiting examples of substituted alkenyl groups.

The term “alkynyl” when used without the “substituted” modifier refers to an monovalent unsaturated aliphatic group with a carbon atom as the point of attachment, a linear or branched, cyclo, cyclic or acyclic structure, at least one carbon-carbon triple bond,
15 and no atoms other than carbon and hydrogen. As used herein, the term alkynyl does not preclude the presence of one or more non-aromatic carbon-carbon double bonds. The groups, -C≡CH, -C≡CCH₃, and -CH₂C≡CCH₃, are non-limiting examples of alkynyl groups. An “alkyne” refers to the compound H-R, wherein R is alkynyl. When any of these terms are used with the “substituted” modifier one or more hydrogen atom has been independently
20 replaced by -OH, -F, -Cl, -Br, -I, -NH₂, -NO₂, -CO₂H, -CO₂CH₃, -CN, -SH, -OCH₃, -OCH₂CH₃, -C(O)CH₃, -NHCH₃, -NHCH₂CH₃, -N(CH₃)₂, -C(O)NH₂, -OC(O)CH₃, or -S(O)₂NH₂.

The term “aryl” when used without the “substituted” modifier refers to a monovalent unsaturated aromatic group with an aromatic carbon atom as the point of attachment, said
25 carbon atom forming part of a one or more six-membered aromatic ring structure, wherein the ring atoms are all carbon, and wherein the group consists of no atoms other than carbon and hydrogen. If more than one ring is present, the rings may be fused or unfused. As used herein, the term does not preclude the presence of one or more alkyl or aralkyl groups (carbon number limitation permitting) attached to the first aromatic ring or any additional
30 aromatic ring present. Non-limiting examples of aryl groups include phenyl (Ph), methylphenyl, (dimethyl)phenyl, -C₆H₄CH₂CH₃ (ethylphenyl), naphthyl, and a monovalent group derived from biphenyl. The term “arenediyl” when used without the “substituted” modifier refers to a divalent aromatic group with two aromatic carbon atoms as points of attachment, said carbon atoms forming part of one or more six-membered aromatic ring

structure(s) wherein the ring atoms are all carbon, and wherein the monovalent group consists of no atoms other than carbon and hydrogen. As used herein, the term does not preclude the presence of one or more alkyl, aryl or aralkyl groups (carbon number limitation permitting) attached to the first aromatic ring or any additional aromatic ring present. If more than one
 5 ring is present, the rings may be fused or unfused. Unfused rings may be connected via one or more of the following: a covalent bond, alkanediyl, or alkenediyl groups (carbon number limitation permitting). Non-limiting examples of arenediyl groups include:




10 An “arene” refers to the compound H-R, wherein R is aryl as that term is defined above. Benzene and toluene are non-limiting examples of arenes. When any of these terms are used with the “substituted” modifier one or more hydrogen atom has been independently replaced by -OH, -F, -Cl, -Br, -I, -NH₂, -NO₂, -CO₂H, -CO₂CH₃, -CN, -SH, -OCH₃, -OCH₂CH₃, -C(O)CH₃, -NHCH₃, -NHCH₂CH₃, -N(CH₃)₂, -C(O)NH₂, -OC(O)CH₃, or
 15 -S(O)₂NH₂.

The term “aralkyl” when used without the “substituted” modifier refers to the monovalent group -alkanediyl-aryl, in which the terms alkanediyl and aryl are each used in a manner consistent with the definitions provided above. Non-limiting examples of aralkyls are: phenylmethyl (benzyl, Bn) and 2-phenyl-ethyl. When the term aralkyl is used with the
 20 “substituted” modifier one or more hydrogen atom from the alkanediyl and/or the aryl group has been independently replaced by -OH, -F, -Cl, -Br, -I, -NH₂, -NO₂, -CO₂H, -CO₂CH₃, -CN, -SH, -OCH₃, -OCH₂CH₃, -C(O)CH₃, -NHCH₃, -NHCH₂CH₃, -N(CH₃)₂, -C(O)NH₂, -OC(O)CH₃, or -S(O)₂NH₂. Non-limiting examples of substituted aralkyls are: (3-chlorophenyl)-methyl, and 2-chloro-2-phenyl-eth-1-yl.

25 The term “heteroaryl” when used without the “substituted” modifier refers to a monovalent aromatic group with an aromatic carbon atom or nitrogen atom as the point of attachment, said carbon atom or nitrogen atom forming part of one or more aromatic ring structures wherein at least one of the ring atoms is nitrogen, oxygen or sulfur, and wherein the heteroaryl group consists of no atoms other than carbon, hydrogen, aromatic nitrogen,
 30 aromatic oxygen and aromatic sulfur. If more than one ring is present, the rings may be fused


or unfused. As used herein, the term does not preclude the presence of one or more alkyl, aryl, and/or aralkyl groups (carbon number limitation permitting) attached to the aromatic ring or aromatic ring system. Non-limiting examples of heteroaryl groups include furanyl, imidazolyl, indolyl, indazolyl (Im), isoxazolyl, methylpyridinyl, oxazolyl, phenylpyridinyl, pyridinyl, pyrrolyl, pyrimidinyl, pyrazinyl, quinolyl, quinazolyl, quinoxalinyl, triazinyl, tetrazolyl, thiazolyl, thienyl, and triazolyl. The term “N-heteroaryl” refers to a heteroaryl group with a nitrogen atom as the point of attachment. The term “heteroarenediyl” when used without the “substituted” modifier refers to an divalent aromatic group, with two aromatic carbon atoms, two aromatic nitrogen atoms, or one aromatic carbon atom and one aromatic nitrogen atom as the two points of attachment, said atoms forming part of one or more aromatic ring structure(s) wherein at least one of the ring atoms is nitrogen, oxygen or sulfur, and wherein the divalent group consists of no atoms other than carbon, hydrogen, aromatic nitrogen, aromatic oxygen and aromatic sulfur. If more than one ring is present, the rings may be fused or unfused. Unfused rings may be connected via one or more of the following: a covalent bond, alkanediyl, or alkenediyl groups (carbon number limitation permitting). As used herein, the term does not preclude the presence of one or more alkyl, aryl, and/or aralkyl groups (carbon number limitation permitting) attached to the aromatic ring or aromatic ring system. Non-limiting examples of heteroarenediyl groups include:



A “heteroarene” refers to the compound H-R, wherein R is heteroaryl. Pyridine and quinoline are non-limiting examples of heteroarenes. When these terms are used with the “substituted” modifier one or more hydrogen atom has been independently replaced by -OH, -F, -Cl, -Br, -I, -NH₂, -NO₂, -CO₂H, -CO₂CH₃, -CN, -SH, -OCH₃, -OCH₂CH₃, -C(O)CH₃, -NHCH₃, -NHCH₂CH₃, -N(CH₃)₂, -C(O)NH₂, -OC(O)CH₃, or -S(O)₂NH₂.

The term “heterocycloalkyl” when used without the “substituted” modifier refers to a monovalent non-aromatic group with a carbon atom or nitrogen atom as the point of attachment, said carbon atom or nitrogen atom forming part of one or more non-aromatic ring structures wherein at least one of the ring atoms is nitrogen, oxygen or sulfur, and wherein the heterocycloalkyl group consists of no atoms other than carbon, hydrogen, nitrogen, oxygen and sulfur. If more than one ring is present, the rings may be fused or unfused. As used herein, the term does not preclude the presence of one or more alkyl groups (carbon number limitation permitting) attached to the ring or ring system. Also, the term does not

preclude the presence of one or more double bonds in the ring or ring system, provided that the resulting group remains non-aromatic. Non-limiting examples of heterocycloalkyl groups include aziridinyl, azetidiny, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, tetrahydrofuranyl, tetrahydrothiofuranyl, tetrahydropyranyl, pyranyl, oxiranyl, and oxetanyl. The term “N-heterocycloalkyl” refers to a heterocycloalkyl group with a nitrogen atom as the point of attachment. The term “heterocycloalkanediy” when used without the “substituted” modifier refers to an divalent cyclic group, with two carbon atoms, two nitrogen atoms, or one carbon atom and one nitrogen atom as the two points of attachment, said atoms forming part of one or more ring structure(s) wherein at least one of the ring atoms is nitrogen, oxygen or sulfur, and wherein the divalent group consists of no atoms other than carbon, hydrogen, nitrogen, oxygen and sulfur. If more than one ring is present, the rings may be fused or unfused. Unfused rings may be connected via one or more of the following: a covalent bond, alkanediy, or alkenediy groups (carbon number limitation permitting). As used herein, the term does not preclude the presence of one or more alkyl groups (carbon number limitation permitting) attached to the ring or ring system. Also, the term does not preclude the presence of one or more double bonds in the ring or ring system, provided that the resulting group remains non-aromatic. Non-limiting examples of heterocycloalkanediy groups include:



When these terms are used with the “substituted” modifier one or more hydrogen atom has been independently replaced by $-\text{OH}$, $-\text{F}$, $-\text{Cl}$, $-\text{Br}$, $-\text{I}$, $-\text{NH}_2$, $-\text{NO}_2$, $-\text{CO}_2\text{H}$, $-\text{CO}_2\text{CH}_3$, $-\text{CN}$, $-\text{SH}$, $-\text{OCH}_3$, $-\text{OCH}_2\text{CH}_3$, $-\text{C}(\text{O})\text{CH}_3$, $-\text{NHCH}_3$, $-\text{NHCH}_2\text{CH}_3$, $-\text{N}(\text{CH}_3)_2$, $-\text{C}(\text{O})\text{NH}_2$, $-\text{OC}(\text{O})\text{CH}_3$, $-\text{S}(\text{O})_2\text{NH}_2$, or $-\text{C}(\text{O})\text{OC}(\text{CH}_3)_3$ (*tert*-butyloxycarbonyl, BOC).

The term “acyl” when used without the “substituted” modifier refers to the group $-\text{C}(\text{O})\text{R}$, in which R is a hydrogen, alkyl, aryl, aralkyl or heteroaryl, as those terms are defined above. The groups, $-\text{CHO}$, $-\text{C}(\text{O})\text{CH}_3$ (acetyl, Ac), $-\text{C}(\text{O})\text{CH}_2\text{CH}_3$, $-\text{C}(\text{O})\text{CH}_2\text{CH}_2\text{CH}_3$, $-\text{C}(\text{O})\text{CH}(\text{CH}_3)_2$, $-\text{C}(\text{O})\text{CH}(\text{CH}_2)_2$, $-\text{C}(\text{O})\text{C}_6\text{H}_5$, $-\text{C}(\text{O})\text{C}_6\text{H}_4\text{CH}_3$, $-\text{C}(\text{O})\text{CH}_2\text{C}_6\text{H}_5$, $-\text{C}(\text{O})(\text{imidazolyl})$ are non-limiting examples of acyl groups. A “thioacyl” is defined in an analogous manner, except that the oxygen atom of the group $-\text{C}(\text{O})\text{R}$ has been replaced with a sulfur atom, $-\text{C}(\text{S})\text{R}$. The term “aldehyde” corresponds to an alkane, as defined above, wherein at least one of the hydrogen atoms has been replaced with a $-\text{CHO}$ group. When any of these terms are used with the “substituted” modifier one or more

hydrogen atom (including a hydrogen atom directly attached the carbonyl or thiocarbonyl group, if any) has been independently replaced by $-\text{OH}$, $-\text{F}$, $-\text{Cl}$, $-\text{Br}$, $-\text{I}$, $-\text{NH}_2$, $-\text{NO}_2$, $-\text{CO}_2\text{H}$, $-\text{CO}_2\text{CH}_3$, $-\text{CN}$, $-\text{SH}$, $-\text{OCH}_3$, $-\text{OCH}_2\text{CH}_3$, $-\text{C}(\text{O})\text{CH}_3$, $-\text{NHCH}_3$, $-\text{NHCH}_2\text{CH}_3$, $-\text{N}(\text{CH}_3)_2$, $-\text{C}(\text{O})\text{NH}_2$, $-\text{OC}(\text{O})\text{CH}_3$, or $-\text{S}(\text{O})_2\text{NH}_2$. The groups, $-\text{C}(\text{O})\text{CH}_2\text{CF}_3$, $-\text{CO}_2\text{H}$ (carboxyl), $-\text{CO}_2\text{CH}_3$ (methylcarboxyl), $-\text{CO}_2\text{CH}_2\text{CH}_3$, $-\text{C}(\text{O})\text{NH}_2$ (carbamoyl), and $-\text{CON}(\text{CH}_3)_2$, are non-limiting examples of substituted acyl groups.

The term “alkoxy” when used without the “substituted” modifier refers to the group $-\text{OR}$, in which R is an alkyl, as that term is defined above. Non-limiting examples of alkoxy groups include: $-\text{OCH}_3$ (methoxy), $-\text{OCH}_2\text{CH}_3$ (ethoxy), $-\text{OCH}_2\text{CH}_2\text{CH}_3$, $-\text{OCH}(\text{CH}_3)_2$ (isopropoxy), $-\text{O}(\text{CH}_3)_3$ (*tert*-butoxy), $-\text{OCH}(\text{CH}_2)_2$, $-\text{O}$ -cyclopentyl, and $-\text{O}$ -cyclohexyl. The terms “alkenyloxy”, “alkynyloxy”, “aryloxy”, “aralkoxy”, “heteroaryloxy”, “heterocycloalkoxy”, and “acyloxy”, when used without the “substituted” modifier, refers to groups, defined as $-\text{OR}$, in which R is alkenyl, alkynyl, aryl, aralkyl, heteroaryl, heterocycloalkyl, and acyl, respectively. The term “alkoxydiyl” refers to the divalent group $-\text{O}$ -alkanediyl-, $-\text{O}$ -alkanediyl- O -, or $-\text{alkanediyl}$ - O -alkanediyl-. The term “alkylthio” and “acylthio” when used without the “substituted” modifier refers to the group $-\text{SR}$, in which R is an alkyl and acyl, respectively. The term “alcohol” corresponds to an alkane, as defined above, wherein at least one of the hydrogen atoms has been replaced with a hydroxy group. The term “ether” corresponds to an alkane, as defined above, wherein at least one of the hydrogen atoms has been replaced with an alkoxy group. When any of these terms is used with the “substituted” modifier one or more hydrogen atom has been independently replaced by $-\text{OH}$, $-\text{F}$, $-\text{Cl}$, $-\text{Br}$, $-\text{I}$, $-\text{NH}_2$, $-\text{NO}_2$, $-\text{CO}_2\text{H}$, $-\text{CO}_2\text{CH}_3$, $-\text{CN}$, $-\text{SH}$, $-\text{OCH}_3$, $-\text{OCH}_2\text{CH}_3$, $-\text{C}(\text{O})\text{CH}_3$, $-\text{NHCH}_3$, $-\text{NHCH}_2\text{CH}_3$, $-\text{N}(\text{CH}_3)_2$, $-\text{C}(\text{O})\text{NH}_2$, $-\text{OC}(\text{O})\text{CH}_3$, or $-\text{S}(\text{O})_2\text{NH}_2$.

The term “alkylamino” when used without the “substituted” modifier refers to the group $-\text{NHR}$, in which R is an alkyl, as that term is defined above. Non-limiting examples of alkylamino groups include: $-\text{NHCH}_3$ and $-\text{NHCH}_2\text{CH}_3$. The term “dialkylamino” when used without the “substituted” modifier refers to the group $-\text{NRR}'$, in which R and R' can be the same or different alkyl groups, or R and R' can be taken together to represent an alkanediyl. Non-limiting examples of dialkylamino groups include: $-\text{N}(\text{CH}_3)_2$, $-\text{N}(\text{CH}_3)(\text{CH}_2\text{CH}_3)$, and *N*-pyrrolidinyl. The terms “alkoxyamino”, “alkenylamino”, “alkynylamino”, “arylamino”, “aralkylamino”, “heteroarylamino”, “heterocycloalkylamino” and “alkylsulfonylamino” when used without the “substituted” modifier, refers to groups, defined as $-\text{NHR}$, in which R is alkoxy, alkenyl, alkynyl, aryl, aralkyl, heteroaryl,

heterocycloalkyl, and alkylsulfonyl, respectively. A non-limiting example of an arylamino group is $-\text{NHC}_6\text{H}_5$. The term “amido” (acylamino), when used without the “substituted” modifier, refers to the group $-\text{NHR}$, in which R is acyl, as that term is defined above. A non-limiting example of an amido group is $-\text{NHC}(\text{O})\text{CH}_3$. The term “alkylimino” when used without the “substituted” modifier refers to the divalent group $=\text{NR}$, in which R is an alkyl, as that term is defined above. The term “alkylaminodiyl” refers to the divalent group $-\text{NH}-\text{alkanediy}-\text{NH}-$, $-\text{NH}-\text{alkanediy}-\text{NH}-$, or $-\text{alkanediy}-\text{NH}-\text{alkanediy}-$. When any of these terms is used with the “substituted” modifier one or more hydrogen atom has been independently replaced by $-\text{OH}$, $-\text{F}$, $-\text{Cl}$, $-\text{Br}$, $-\text{I}$, $-\text{NH}_2$, $-\text{NO}_2$, $-\text{CO}_2\text{H}$, $-\text{CO}_2\text{CH}_3$, $-\text{CN}$, $-\text{SH}$, $-\text{OCH}_3$, $-\text{OCH}_2\text{CH}_3$, $-\text{C}(\text{O})\text{CH}_3$, $-\text{NHCH}_3$, $-\text{NHCH}_2\text{CH}_3$, $-\text{N}(\text{CH}_3)_2$, $-\text{C}(\text{O})\text{NH}_2$, $-\text{OC}(\text{O})\text{CH}_3$, or $-\text{S}(\text{O})_2\text{NH}_2$. The groups $-\text{NHC}(\text{O})\text{OCH}_3$ and $-\text{NHC}(\text{O})\text{NHCH}_3$ are non-limiting examples of substituted amido groups.

The terms “alkylsulfonyl” and “alkylsulfinyl” when used without the “substituted” modifier refers to the groups $-\text{S}(\text{O})_2\text{R}$ and $-\text{S}(\text{O})\text{R}$, respectively, in which R is an alkyl, as that term is defined above. The terms “alkenylsulfonyl”, “alkynylsulfonyl”, “arylsulfonyl”, “aralkylsulfonyl”, “heteroarylsulfonyl”, and “heterocycloalkylsulfonyl” are defined in an analogous manner. When any of these terms is used with the “substituted” modifier one or more hydrogen atom has been independently replaced by $-\text{OH}$, $-\text{F}$, $-\text{Cl}$, $-\text{Br}$, $-\text{I}$, $-\text{NH}_2$, $-\text{NO}_2$, $-\text{CO}_2\text{H}$, $-\text{CO}_2\text{CH}_3$, $-\text{CN}$, $-\text{SH}$, $-\text{OCH}_3$, $-\text{OCH}_2\text{CH}_3$, $-\text{C}(\text{O})\text{CH}_3$, $-\text{NHCH}_3$, $-\text{NHCH}_2\text{CH}_3$, $-\text{N}(\text{CH}_3)_2$, $-\text{C}(\text{O})\text{NH}_2$, $-\text{OC}(\text{O})\text{CH}_3$, or $-\text{S}(\text{O})_2\text{NH}_2$.

The term “alkylphosphate” when used without the “substituted” modifier refers to the group $-\text{OP}(\text{O})(\text{OH})(\text{OR})$, in which R is an alkyl, as that term is defined above. Non-limiting examples of alkylphosphate groups include: $-\text{OP}(\text{O})(\text{OH})(\text{OMe})$ and $-\text{OP}(\text{O})(\text{OH})(\text{OEt})$. The term “dialkylphosphate” when used without the “substituted” modifier refers to the group $-\text{OP}(\text{O})(\text{OR})(\text{OR}')$, in which R and R' can be the same or different alkyl groups, or R and R' can be taken together to represent an alkanediyl. Non-limiting examples of dialkylphosphate groups include: $-\text{OP}(\text{O})(\text{OMe})_2$, $-\text{OP}(\text{O})(\text{OEt})(\text{OMe})$ and $-\text{OP}(\text{O})(\text{OEt})_2$. When any of these terms is used with the “substituted” modifier one or more hydrogen atom has been independently replaced by $-\text{OH}$, $-\text{F}$, $-\text{Cl}$, $-\text{Br}$, $-\text{I}$, $-\text{NH}_2$, $-\text{NO}_2$, $-\text{CO}_2\text{H}$, $-\text{CO}_2\text{CH}_3$, $-\text{CN}$, $-\text{SH}$, $-\text{OCH}_3$, $-\text{OCH}_2\text{CH}_3$, $-\text{C}(\text{O})\text{CH}_3$, $-\text{NHCH}_3$, $-\text{NHCH}_2\text{CH}_3$, $-\text{N}(\text{CH}_3)_2$, $-\text{C}(\text{O})\text{NH}_2$, $-\text{OC}(\text{O})\text{CH}_3$, or $-\text{S}(\text{O})_2\text{NH}_2$.

The use of the word “a” or “an,” when used in conjunction with the term “comprising” in the claims and/or the specification may mean “one,” but it is also consistent with the meaning of “one or more,” “at least one,” and “one or more than one.”

Throughout this application, the term “about” is used to indicate that a value includes the inherent variation of error for the device, the method being employed to determine the value, or the variation that exists among the study subjects.

As used herein, a “chiral auxiliary” refers to a removable chiral group that is capable
5 of influencing the stereoselectivity of a reaction. Persons of skill in the art are familiar with such compounds, and many are commercially available.

The terms “comprise,” “have” and “include” are open-ended linking verbs. Any forms or tenses of one or more of these verbs, such as “comprises,” “comprising,” “has,” “having,” “includes” and “including,” are also open-ended. For example, any method that
10 “comprises,” “has” or “includes” one or more steps is not limited to possessing only those one or more steps and also covers other unlisted steps.

The term “effective,” as that term is used in the specification and/or claims, means adequate to accomplish a desired, expected, or intended result. “Effective amount,” “Therapeutically effective amount” or “pharmaceutically effective amount” when used in the
15 context of treating a patient or subject with a compound means that amount of the compound which, when administered to a subject or patient for treating a disease, is sufficient to effect such treatment for the disease.

As used herein, the term “IC₅₀” refers to an inhibitory dose which is 50% of the maximum response obtained. This quantitative measure indicates how much of a particular
20 drug or other substance (inhibitor) is needed to inhibit a given biological, biochemical or chemical process (or component of a process, i.e. an enzyme, cell, cell receptor or microorganism) by half.

An “isomer” of a first compound is a separate compound in which each molecule contains the same constituent atoms as the first compound, but where the configuration of
25 those atoms in three dimensions differs.

As used herein, the term “patient” or “subject” refers to a living mammalian organism, such as a human, monkey, cow, sheep, goat, dog, cat, mouse, rat, guinea pig, or transgenic species thereof. In certain embodiments, the patient or subject is a primate. Non-limiting examples of human subjects are adults, juveniles, infants and fetuses.

As generally used herein “pharmaceutically acceptable” refers to those compounds,
30 materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues, organs, and/or bodily fluids of human beings and animals without excessive toxicity, irritation, allergic response, or other problems or complications commensurate with a reasonable benefit/risk ratio.

“Pharmaceutically acceptable salts” means salts of compounds of the present invention which are pharmaceutically acceptable, as defined above, and which possess the desired pharmacological activity. Such salts include acid addition salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or with organic acids such as 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, 2-naphthalenesulfonic acid, 3-phenylpropionic acid, 4,4'-methylenebis(3-hydroxy-2-ene-1-carboxylic acid), 4-methylbicyclo[2.2.2]oct-2-ene-1-carboxylic acid, acetic acid, aliphatic mono- and dicarboxylic acids, aliphatic sulfuric acids, aromatic sulfuric acids, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, carbonic acid, cinnamic acid, citric acid, cyclopentanepropionic acid, ethanesulfonic acid, fumaric acid, glucoheptonic acid, gluconic acid, glutamic acid, glycolic acid, heptanoic acid, hexanoic acid, hydroxynaphthoic acid, lactic acid, laurylsulfuric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, muconic acid, *o*-(4-hydroxybenzoyl)benzoic acid, oxalic acid, *p*-chlorobenzenesulfonic acid, phenyl-substituted alkanoic acids, propionic acid, *p*-toluenesulfonic acid, pyruvic acid, salicylic acid, stearic acid, succinic acid, tartaric acid, tertiarybutylacetic acid, trimethylacetic acid, and the like. Pharmaceutically acceptable salts also include base addition salts which may be formed when acidic protons present are capable of reacting with inorganic or organic bases. Acceptable inorganic bases include sodium hydroxide, sodium carbonate, potassium hydroxide, aluminum hydroxide and calcium hydroxide. Acceptable organic bases include ethanolamine, diethanolamine, triethanolamine, tromethamine, *N*-methylglucamine and the like. It should be recognized that the particular anion or cation forming a part of any salt of this invention is not critical, so long as the salt, as a whole, is pharmacologically acceptable. Additional examples of pharmaceutically acceptable salts and their methods of preparation and use are presented in *Handbook of Pharmaceutical Salts: Properties, and Use* (P. H. Stahl & C. G. Wermuth eds., Verlag Helvetica Chimica Acta, 2002).

The term “pharmaceutically acceptable carrier,” as used herein means a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting a chemical agent.

“Prevention” or “preventing” includes: (1) inhibiting the onset of a disease in a subject or patient which may be at risk and/or predisposed to the disease but does not yet experience or display any or all of the pathology or symptomatology of the disease, and/or (2) slowing the onset of the pathology or symptomatology of a disease in a subject or patient

which may be at risk and/or predisposed to the disease but does not yet experience or display any or all of the pathology or symptomatology of the disease.

“Prodrug” means a compound that is convertible *in vivo* metabolically into an inhibitor according to the present invention. The prodrug itself may or may not also have activity with respect to a given target protein. For example, a compound comprising a hydroxy group may be administered as an ester that is converted by hydrolysis *in vivo* to the hydroxy compound. Suitable esters that may be converted *in vivo* into hydroxy compounds include acetates, citrates, lactates, phosphates, tartrates, malonates, oxalates, salicylates, propionates, succinates, fumarates, maleates, methylene-bis- β -hydroxynaphthoate, gentisates, isethionates, di-*p*-toluoyltartrates, methanesulfonates, ethanesulfonates, benzenesulfonates, *p*-toluenesulfonates, cyclohexylsulfamates, quinates, esters of amino acids, and the like. Similarly, a compound comprising an amine group may be administered as an amide that is converted by hydrolysis *in vivo* to the amine compound.

A “stereoisomer” or “optical isomer” is an isomer of a given compound in which the same atoms are bonded to the same other atoms, but where the configuration of those atoms in three dimensions differs. “Enantiomers” are stereoisomers of a given compound that are mirror images of each other, like left and right hands. “Diastereomers” are stereoisomers of a given compound that are not enantiomers. Chiral molecules contain a chiral center, also referred to as a stereocenter or stereogenic center, which is any point, though not necessarily an atom, in a molecule bearing groups such that an interchanging of any two groups leads to a stereoisomer. In organic compounds, the chiral center is typically a carbon, phosphorus or sulfur atom, though it is also possible for other atoms to be stereocenters in organic and inorganic compounds. A molecule can have multiple stereocenters, giving it many stereoisomers. In compounds whose stereoisomerism is due to tetrahedral stereogenic centers (*e.g.*, tetrahedral carbon), the total number of hypothetically possible stereoisomers will not exceed 2^n , where n is the number of tetrahedral stereocenters. Molecules with symmetry frequently have fewer than the maximum possible number of stereoisomers. A 50:50 mixture of enantiomers is referred to as a racemic mixture. Alternatively, a mixture of enantiomers can be enantiomerically enriched so that one enantiomer is present in an amount greater than 50%. Typically, enantiomers and/or diastereomers can be resolved or separated using techniques known in the art. It is contemplated that for any stereocenter or axis of chirality for which stereochemistry has not been defined, that stereocenter or axis of chirality can be present in its *R* form, *S* form, or as a mixture of the *R* and *S* forms, including racemic

and non-racemic mixtures. As used herein, the phrase “substantially free from other stereoisomers” means that the composition contains $\leq 15\%$, more preferably $\leq 10\%$, even more preferably $\leq 5\%$, or most preferably $\leq 1\%$ of another stereoisomer(s).

“Treatment” or “treating” includes (1) inhibiting a disease in a subject or patient
5 experiencing or displaying the pathology or symptomatology of the disease (*e.g.*, arresting further development of the pathology and/or symptomatology), (2) ameliorating a disease in a subject or patient that is experiencing or displaying the pathology or symptomatology of the disease (*e.g.*, reversing the pathology and/or symptomatology), and/or (3) effecting any measurable decrease in a disease in a subject or patient that is experiencing or displaying the
10 pathology or symptomatology of the disease.

Other abbreviations used herein are as follows: DMSO, dimethyl sulfoxide; LiAlH_4 , lithium aluminum hydride; DMF, dimethylformamide; MeCN, acetonitrile; MeOH, methanol; EtOH, ethanol; EtOAc, ethyl acetate; $t\text{BuOH}$, tert-butanol; $i\text{PrOH}$, isopropanol; $\text{C}_6\text{H}_{11}\text{OH}$, cyclohexanol; Pd/C, palladium on carbon; Ac_2O , acetic anhydride; AcOOH ,
15 peracetic acid; HCO_2Et , ethyl formate; MeOTf, methyl trifluoromethanesulfonate; EtNCO, ethyl isocyanate; THF, tetrahydrofuran; KO^tBu , potassium tert-butoxide; NaOMe, sodium methoxide; MTBE, methyl tert-butyl ether; DME, dimethoxyethane; NBS, N-bromosuccinimide; DIBAL-H, diisobutylaluminum hydride; CDI, carbonyldiimidazole; DIEA, diisopropylethylamine; $\text{HOBt} \cdot x\text{H}_2\text{O}$, hydroxybenzotriazole hydrate; TEA,
20 triethylamine; DMAP, dimethylaminopyridine; EDCI, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide; 4 Å MS, 4 angstrom molecular sieves; NMO, N-methylmorpholine N-oxide; TPAP, tetrapropylammonium perruthenate; DBDMH, 1,3-dibromo-5,5-dimethylhydantoin; NO, nitric oxide; iNOS, inducible nitric oxide synthase; COX-2, cyclooxygenase-2; FBS, fetal bovine serum; $\text{IFN}\gamma$ or $\text{IFN-}\gamma$, interferon- γ ; $\text{TNF}\alpha$ or
25 $\text{TNF-}\alpha$, tumor necrosis factor- α ; $\text{IL-1}\beta$, interleukin-1 β ; HO-1, inducible heme oxygenase.

The above definitions supersede any conflicting definition in any of the reference that is incorporated by reference herein. The fact that certain terms are defined, however, should not be considered as indicative that any term that is undefined is indefinite. Rather, all terms used are believed to describe the invention in terms such that one of ordinary skill can
30 appreciate the scope and practice the present invention.

II. Compounds and Synthetic Methods

The compounds provided by the present disclosure are shown above in the summary of the invention, in the claims, and in the sections below. They may be made using the

methods outlined in the Examples section. These methods can be further modified and optimized using the principles and techniques of organic chemistry as applied by a person skilled in the art. Such principles and techniques are taught, for example, in *March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure* (2007), which is
5 incorporated by reference herein.

Compounds of the invention may contain one or more asymmetrically-substituted carbon or nitrogen atoms, and may be isolated in optically active or racemic form. Thus, all chiral, diastereomeric, racemic form, epimeric form, and all geometric isomeric forms of a chemical formula are intended, unless the specific stereochemistry or isomeric form is
10 specifically indicated. Compounds may occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. In some embodiments, a single diastereomer is obtained. The chiral centers of the compounds of the present invention can have the *S* or the *R* configuration.

Chemical formulas used to represent compounds of the invention will typically only
15 show one of possibly several different tautomers. For example, many types of ketone groups are known to exist in equilibrium with corresponding enol groups. Similarly, many types of imine groups exist in equilibrium with enamine groups. Regardless of which tautomer is depicted for a given compound, and regardless of which one is most prevalent, all tautomers of a given chemical formula are intended.

20 Atoms making up the compounds of the present invention are intended to include all isotopic forms of such atoms. Compounds of the present invention include those with one or more atoms that have been isotopically modified or enriched, in particular those with pharmaceutically acceptable isotopes or those useful for pharmaceutically research. Isotopes, as used herein, include those atoms having the same atomic number but different mass
25 numbers. By way of general example and without limitation, isotopes of hydrogen include deuterium and tritium, and isotopes of carbon include ^{13}C and ^{14}C . Similarly, it is contemplated that one or more carbon atom(s) of a compound of the present invention may be replaced by a silicon atom(s). Furthermore, it is contemplated that one or more oxygen atom(s) of a compound of the present invention may be replaced by a sulfur or selenium
30 atom(s).

Compounds of the present invention may also exist in prodrug form. Since prodrugs are known to enhance numerous desirable qualities of pharmaceuticals (*e.g.*, solubility, bioavailability, manufacturing, etc.), the compounds employed in some methods of the invention may, if desired, be delivered in prodrug form. Thus, the invention contemplates

prodrugs of compounds of the present invention as well as methods of delivering prodrugs. Prodrugs of the compounds employed in the invention may be prepared by modifying functional groups present in the compound in such a way that the modifications are cleaved, either in routine manipulation or *in vivo*, to the parent compound. Accordingly, prodrugs
5 include, for example, compounds described herein in which a hydroxy, amino, or carboxy group is bonded to any group that, when the prodrug is administered to a subject, cleaves to form a hydroxy, amino, or carboxylic acid, respectively.

It should be recognized that the particular anion or cation forming a part of any salt of this invention is not critical, so long as the salt, as a whole, is pharmacologically acceptable.
10 Additional examples of pharmaceutically acceptable salts and their methods of preparation and use are presented in *Handbook of Pharmaceutical Salts: Properties, and Use* (2002), which is incorporated herein by reference.

It should be further recognized that the compounds of the present invention include those that have been further modified to comprise substituents that are convertible to
15 hydrogen *in vivo*. This includes those groups that may be convertible to a hydrogen atom by enzymological or chemical means including, but not limited to, hydrolysis and hydrogenolysis. Examples include hydrolyzable groups, such as acyl groups, groups having an oxycarbonyl group, amino acid residues, peptide residues, *o*-nitrophenylsulfenyl, trimethylsilyl, tetrahydropyranyl, diphenylphosphinyl, and the like. Examples of acyl groups
20 include formyl, acetyl, trifluoroacetyl, and the like. Examples of groups having an oxycarbonyl group include ethoxycarbonyl, *tert*-butoxycarbonyl ($-\text{C}(\text{O})\text{OC}(\text{CH}_3)_3$, Boc), benzyloxycarbonyl, *p*-methoxybenzyloxycarbonyl, vinyloxycarbonyl, β -(*p*-toluenesulfonyl)ethoxycarbonyl, and the like. Suitable amino acid residues include, but are not limited to, residues of Gly (glycine), Ala (alanine), Arg (arginine), Asn (asparagine), Asp
25 (aspartic acid), Cys (cysteine), Glu (glutamic acid), His (histidine), Ile (isoleucine), Leu (leucine), Lys (lysine), Met (methionine), Phe (phenylalanine), Pro (proline), Ser (serine), Thr (threonine), Trp (tryptophan), Tyr (tyrosine), Val (valine), Nva (norvaline), Hse (homoserine), 4-Hyp (4-hydroxyproline), 5-Hyl (5-hydroxylysine), Orn (ornithine) and β -Ala. Examples of suitable amino acid residues also include amino acid residues that are
30 protected with a protecting group. Examples of suitable protecting groups include those typically employed in peptide synthesis, including acyl groups (such as formyl and acetyl), arylmethoxycarbonyl groups (such as benzyloxycarbonyl and *p*-nitrobenzyloxycarbonyl), *tert*-butoxycarbonyl groups ($-\text{C}(\text{O})\text{OC}(\text{CH}_3)_3$, Boc), and the like. Suitable peptide residues include peptide residues comprising two to five amino acid residues. The residues of these

amino acids or peptides can be present in stereochemical configurations of the D-form, the L-form or mixtures thereof. In addition, the amino acid or peptide residue may have an asymmetric carbon atom. Examples of suitable amino acid residues having an asymmetric carbon atom include residues of Ala, Leu, Phe, Trp, Nva, Val, Met, Ser, Lys, Thr and Tyr.




- 5 Peptide residues having an asymmetric carbon atom include peptide residues having one or more constituent amino acid residues having an asymmetric carbon atom. Examples of suitable amino acid protecting groups include those typically employed in peptide synthesis, including acyl groups (such as formyl and acetyl), arylmethoxycarbonyl groups (such as benzyloxycarbonyl and *p*-nitrobenzyloxycarbonyl), *tert*-butoxycarbonyl groups
10 $(-C(O)OC(CH_3)_3)$, and the like. Other examples of substituents “convertible to hydrogen *in vivo*” include reductively eliminable hydrogenolyzable groups. Examples of suitable reductively eliminable hydrogenolyzable groups include, but are not limited to, arylsulfonyl groups (such as *o*-toluenesulfonyl); methyl groups substituted with phenyl or benzyloxy (such as benzyl, trityl and benzyloxymethyl); arylmethoxycarbonyl groups (such as
15 benzyloxycarbonyl and *o*-methoxy-benzyloxycarbonyl); and haloethoxycarbonyl groups (such as β,β,β -trichloroethoxycarbonyl and β -iodoethoxycarbonyl).




Compounds of the invention may also have the advantage that they may be more efficacious than, be less toxic than, be longer acting than, be more potent than, produce fewer side effects than, be more easily absorbed than, and/or have a better pharmacokinetic profile
20 (*e.g.*, higher oral bioavailability and/or lower clearance) than, and/or have other useful pharmacological, physical, or chemical properties over, compounds known in the prior art, whether for use in the indications stated herein or otherwise.




III. Biological Activity




Assay results for the suppression of IFN γ -induced NO production are shown for
25 several of the compounds of the present invention in Table 1 below. In the right-hand column of this table under the RAW264.7 heading, the results are compared to those of bardoxolone methyl (RTA 402, CDDO-Me). Details regarding this assay are provided in the Examples section below.




Table 1. Suppression of IFN γ -Induced NO Production.




Compound No.	Molecular Formula	MW	RAW264.7	
			NO IC ₅₀ (nM)	Relative NO IC ₅₀
TX63403		475.71	8.6	4.3
TX63608		491.70	1.1	0.5
TX63609		505.73	2.9	1.2




Compound No.	Molecular Formula	MW	RAW264.7	
			NO IC ₅₀ (nM)	Relative NO IC ₅₀
TX63610		533.74	2.2	0.9
TX63742		533.74	2.0	1.0
TX63743		531.73	3.2	1.6




Compound No.	Molecular Formula	MW	RAW264.7	
			NO IC ₅₀ (nM)	Relative NO IC ₅₀
TX63744		505.73	1.1	0.6
TX63762		519.71	1.2	1.0
TX63763		588.82	0.4	0.3




Compound No.	Molecular Formula	MW	RAW264.7	
			NO IC ₅₀ (nM)	Relative NO IC ₅₀
TX63764		600.75	0.7	0.6
TX63768		546.78	0.3	0.2
TX63770		532.76	0.2	0.2




Compound No.	Molecular Formula	MW	RAW264.7	
			NO IC ₅₀ (nM)	Relative NO IC ₅₀
TX63868		571.77	0.7	0.4
TX63926		590.79	0.7	0.5
TX63927		574.79	1.3	0.9




Compound No.	Molecular Formula	MW	RAW264.7	
			NO IC ₅₀ (nM)	Relative NO IC ₅₀
TX63930		548.76	0.9	0.6
TX63949		572.82	0.6	0.5
TX63950		558.79	0.4	0.3




Compound No.	Molecular Formula	MW	RAW264.7	
			NO IC ₅₀ (nM)	Relative NO IC ₅₀
TX63981		562.78	3.0	1.2
TX63983		576.81	5.4	2.1
TX64042		547.77	10	3.5




Compound No.	Molecular Formula	MW	RAW264.7	
			NO IC ₅₀ (nM)	Relative NO IC ₅₀
TX64043		561.79	21	7.1
TX64044		574.79	1.3	0.4
TX64045		575.78	5.6	1.9




Compound No.	Molecular Formula	MW	RAW264.7	
			NO IC ₅₀ (nM)	Relative NO IC ₅₀
TX64046		595.81	8.5	2.9
TX64047		588.82	3.3	1.1
TX64048		602.85	1.2	0.4




Compound No.	Molecular Formula	MW	RAW264.7	
			NO IC ₅₀ (nM)	Relative NO IC ₅₀
TX64049		608.80	2.0	0.7
TX64052		590.79	2.0	0.7
TX64053		702.96	37	13

Compound No.	Molecular Formula	MW	RAW264.7	
			NO IC ₅₀ (nM)	Relative NO IC ₅₀
TX64054		576.77	97	56
TX64055		602.85	1.7	1.2
TX64056		548.76	0.3	0.2

Compound No.	Molecular Formula	MW	RAW264.7	
			NO IC ₅₀ (nM)	Relative NO IC ₅₀
TX64057		600.87	0.8	0.4
TX64058		601.86	29	20
TX64059		594.83	1.4	0.8

Compound No.	Molecular Formula	MW	RAW264.7	
			NO IC ₅₀ (nM)	Relative NO IC ₅₀
TX64060		546.78	0.4	0.2
TX64064		560.81	0.4	0.2
TX64065		574.84	0.6	0.3

Compound No.	Molecular Formula	MW	RAW264.7	
			NO IC ₅₀ (nM)	Relative NO IC ₅₀
TX64066		609.84	20	13.8
TX64067		575.82	14	10
TX64068		595.81	1.1	0.8

Compound No.	Molecular Formula	MW	RAW264.7	
			NO IC ₅₀ (nM)	Relative NO IC ₅₀
TX64074		518.73	0.3	0.3
TX64124		687.95	3.4	2.2
TX64135		587.84	1.5	1.0

IV. Diseases Associated with Inflammation and/or Oxidative Stress

Inflammation is a biological process that provides resistance to infectious or parasitic organisms and the repair of damaged tissue. Inflammation is commonly characterized by localized vasodilation, redness, swelling, and pain, the recruitment of leukocytes to the site of infection or injury, production of inflammatory cytokines such as TNF- α and IL-1, and production of reactive oxygen or nitrogen species such as hydrogen peroxide, superoxide and peroxynitrite. In later stages of inflammation, tissue remodeling, angiogenesis, and scar formation (fibrosis) may occur as part of the wound healing process. Under normal circumstances, the inflammatory response is regulated and temporary and is resolved in an orchestrated fashion once the infection or injury has been dealt with adequately. However, acute inflammation can become excessive and life-threatening if regulatory mechanisms fail. Alternatively, inflammation can become chronic and cause cumulative tissue damage or systemic complications. Based at least on the evidence presented above, the compounds of this invention may be used in the treatment or prevention of inflammation or diseases associated with inflammation.

Many serious and intractable human diseases involve dysregulation of inflammatory processes, including diseases such as cancer, atherosclerosis, and diabetes, which were not traditionally viewed as inflammatory conditions. In the case of cancer, the inflammatory processes are associated with tumor formation, progression, metastasis, and resistance to therapy. Atherosclerosis, long viewed as a disorder of lipid metabolism, is now understood to be primarily an inflammatory condition, with activated macrophages playing an important role in the formation and eventual rupture of atherosclerotic plaques. Activation of inflammatory signaling pathways has also been shown to play a role in the development of insulin resistance, as well as in the peripheral tissue damage associated with diabetic hyperglycemia. Excessive production of reactive oxygen species and reactive nitrogen species such as superoxide, hydrogen peroxide, nitric oxide, and peroxynitrite is a hallmark of inflammatory conditions. Evidence of dysregulated peroxynitrite production has been reported in a wide variety of diseases (Szabo *et al.*, 2007; Schulz *et al.*, 2008; Forstermann, 2006; Pall, 2007).

Autoimmune diseases such as rheumatoid arthritis, lupus, psoriasis, and multiple sclerosis involve inappropriate and chronic activation of inflammatory processes in affected tissues, arising from dysfunction of self vs. non-self recognition and response mechanisms in the immune system. In neurodegenerative diseases such as Alzheimer's and Parkinson's

diseases, neural damage is correlated with activation of microglia and elevated levels of pro-inflammatory proteins such as inducible nitric oxide synthase (iNOS). Chronic organ failure such as renal failure, heart failure, liver failure, and chronic obstructive pulmonary disease is closely associated with the presence of chronic oxidative stress and inflammation, leading to the development of fibrosis and eventual loss of organ function. Oxidative stress in vascular endothelial cells, which line major and minor blood vessels, can lead to endothelial dysfunction and is believed to be an important contributing factor in the development of systemic cardiovascular disease, complications of diabetes, chronic kidney disease and other forms of organ failure, and a number of other aging-related diseases including degenerative diseases of the central nervous system and the retina.

Many other disorders involve oxidative stress and inflammation in affected tissues, including inflammatory bowel disease; inflammatory skin diseases; mucositis related to radiation therapy and chemotherapy; eye diseases such as uveitis, glaucoma, macular degeneration, and various forms of retinopathy; transplant failure and rejection; ischemia-reperfusion injury; chronic pain; degenerative conditions of the bones and joints including osteoarthritis and osteoporosis; asthma and cystic fibrosis; seizure disorders; and neuropsychiatric conditions including schizophrenia, depression, bipolar disorder, post-traumatic stress disorder, attention deficit disorders, autism-spectrum disorders, and eating disorders such as anorexia nervosa. Dysregulation of inflammatory signaling pathways is believed to be a major factor in the pathology of muscle wasting diseases including muscular dystrophy and various forms of cachexia.

A variety of life-threatening acute disorders also involve dysregulated inflammatory signaling, including acute organ failure involving the pancreas, kidneys, liver, or lungs, myocardial infarction or acute coronary syndrome, stroke, septic shock, trauma, severe burns, and anaphylaxis.

Many complications of infectious diseases also involve dysregulation of inflammatory responses. Although an inflammatory response can kill invading pathogens, an excessive inflammatory response can also be quite destructive and in some cases can be a primary source of damage in infected tissues. Furthermore, an excessive inflammatory response can also lead to systemic complications due to overproduction of inflammatory cytokines such as TNF- α and IL-1. This is believed to be a factor in mortality arising from severe influenza, severe acute respiratory syndrome, and sepsis.

The aberrant or excessive expression of either iNOS or cyclooxygenase-2 (COX-2) has been implicated in the pathogenesis of many disease processes. For example, it is clear that NO is a potent mutagen (Tamir and Tannebaum, 1996), and that nitric oxide can also activate COX-2 (Salvemini *et al.*, 1994). Furthermore, there is a marked increase in iNOS in rat colon tumors induced by the carcinogen, azoxymethane (Takahashi *et al.*, 1997). A series of synthetic triterpenoid analogs of oleanolic acid have been shown to be powerful inhibitors of cellular inflammatory processes, such as the induction by IFN- γ of inducible nitric oxide synthase (iNOS) and of COX-2 in mouse macrophages. See Honda *et al.* (2000a); Honda *et al.* (2000b), and Honda *et al.* (2002), which are all incorporated herein by reference.

In one aspect, compounds disclosed herein are characterized by their ability to inhibit the production of nitric oxide in macrophage-derived RAW 264.7 cells induced by exposure to γ -interferon. They are further characterized by their ability to induce the expression of antioxidant proteins such as NQO1 and reduce the expression of pro-inflammatory proteins such as COX-2 and inducible nitric oxide synthase (iNOS). These properties are relevant to the treatment of a wide array of diseases and disorders involving oxidative stress and dysregulation of inflammatory processes including cancer, complications from localized or total-body exposure to ionizing radiation, mucositis resulting from radiation therapy or chemotherapy, autoimmune diseases, cardiovascular diseases including atherosclerosis, ischemia-reperfusion injury, acute and chronic organ failure including renal failure and heart failure, respiratory diseases, diabetes and complications of diabetes, severe allergies, transplant rejection, graft-versus-host disease, neurodegenerative diseases, diseases of the eye and retina, acute and chronic pain, degenerative bone diseases including osteoarthritis and osteoporosis, inflammatory bowel diseases, dermatitis and other skin diseases, sepsis, burns, seizure disorders, and neuropsychiatric disorders.

Without being bound by theory, the activation of the antioxidant/anti-inflammatory Keap1/Nrf2/ARE pathway is believed to be implicated in both the anti-inflammatory and anti-carcinogenic properties of the compounds disclosed herein.

In another aspect, compounds disclosed herein may be used for treating a subject having a condition caused by elevated levels of oxidative stress in one or more tissues. Oxidative stress results from abnormally high or prolonged levels of reactive oxygen species such as superoxide, hydrogen peroxide, nitric oxide, and peroxynitrite (formed by the reaction of nitric oxide and superoxide). The oxidative stress may be accompanied by either acute or chronic inflammation. The oxidative stress may be caused by mitochondrial

dysfunction, by activation of immune cells such as macrophages and neutrophils, by acute exposure to an external agent such as ionizing radiation or a cytotoxic chemotherapy agent (e.g., doxorubicin), by trauma or other acute tissue injury, by ischemia/reperfusion, by poor circulation or anemia, by localized or systemic hypoxia or hyperoxia, by elevated levels of inflammatory cytokines and other inflammation-related proteins, and/or by other abnormal physiological states such as hyperglycemia or hypoglycemia.

In animal models of many such conditions, stimulating expression of inducible heme oxygenase (HO-1), a target gene of the Nrf2 pathway, has been shown to have a significant therapeutic effect including models of myocardial infarction, renal failure, transplant failure and rejection, stroke, cardiovascular disease, and autoimmune disease (e.g., Sacerdoti *et al.*, 2005; Abraham & Kappas, 2005; Bach, 2006; Araujo *et al.*, 2003; Liu *et al.*, 2006; Ishikawa *et al.*, 2001; Kruger *et al.*, 2006; Satoh *et al.*, 2006; Zhou *et al.*, 2005; Morse and Choi, 2005; Morse and Choi, 2002). This enzyme breaks free heme down into iron, carbon monoxide (CO), and biliverdin (which is subsequently converted to the potent antioxidant molecule, bilirubin).

In another aspect, compounds of this invention may be used in preventing or treating tissue damage or organ failure, acute and chronic, resulting from oxidative stress exacerbated by inflammation. Examples of diseases that fall in this category include: heart failure, liver failure, transplant failure and rejection, renal failure, pancreatitis, fibrotic lung diseases (cystic fibrosis, COPD, and idiopathic pulmonary fibrosis, among others), diabetes (including complications), atherosclerosis, ischemia-reperfusion injury, glaucoma, stroke, autoimmune disease, autism, macular degeneration, and muscular dystrophy. For example, in the case of autism, studies suggest that increased oxidative stress in the central nervous system may contribute to the development of the disease (Chauhan and Chauhan, 2006).

Evidence also links oxidative stress and inflammation to the development and pathology of many other disorders of the central nervous system, including psychiatric disorders such as psychosis, major depression, and bipolar disorder; seizure disorders such as epilepsy; pain and sensory syndromes such as migraine, neuropathic pain or tinnitus; and behavioral syndromes such as the attention deficit disorders. See, e.g., Dickerson *et al.*, 2007; Hanson *et al.*, 2005; Kendall-Tackett, 2007; Lencz *et al.*, 2007; Dudhgaonkar *et al.*, 2006; Lee *et al.*, 2007; Morris *et al.*, 2002; Ruster *et al.*, 2005; McIver *et al.*, 2005; Sarchielli *et al.*, 2006; Kawakami *et al.*, 2006; Ross *et al.*, 2003, which are all incorporated by reference herein. For example, elevated levels of inflammatory cytokines, including TNF, interferon- γ ,

and IL-6, are associated with major mental illness (Dickerson *et al.*, 2007). Microglial activation has also been linked to major mental illness. Therefore, downregulating inflammatory cytokines and inhibiting excessive activation of microglia could be beneficial in patients with schizophrenia, major depression, bipolar disorder, autism-spectrum disorders, and other neuropsychiatric disorders.

Accordingly, in pathologies involving oxidative stress alone or oxidative stress exacerbated by inflammation, treatment may comprise administering to a subject a therapeutically effective amount of a compound of this invention, such as those described above or throughout this specification. Treatment may be administered preventively, in advance of a predictable state of oxidative stress (*e.g.*, organ transplantation or the administration of radiation therapy to a cancer patient), or it may be administered therapeutically in settings involving established oxidative stress and inflammation.

The compounds disclosed herein may be generally applied to the treatment of inflammatory conditions, such as sepsis, dermatitis, autoimmune disease and osteoarthritis. In one aspect, the compounds of this invention may be used to treat inflammatory pain and/or neuropathic pain, for example, by inducing Nrf2 and/or inhibiting NF- κ B.

In some embodiments, the compounds disclosed herein may be used in the treatment and prevention of diseases such as cancer, inflammation, Alzheimer's disease, Parkinson's disease, multiple sclerosis, autism, amyotrophic lateral sclerosis, Huntington's disease, autoimmune diseases such as rheumatoid arthritis, lupus, Crohn's disease and psoriasis, inflammatory bowel disease, all other diseases whose pathogenesis is believed to involve excessive production of either nitric oxide or prostaglandins, and pathologies involving oxidative stress alone or oxidative stress exacerbated by inflammation.

Another aspect of inflammation is the production of inflammatory prostaglandins such as prostaglandin E. These molecules promote vasodilation, plasma extravasation, localized pain, elevated temperature, and other symptoms of inflammation. The inducible form of the enzyme COX-2 is associated with their production, and high levels of COX-2 are found in inflamed tissues. Consequently, inhibition of COX-2 may relieve many symptoms of inflammation and a number of important anti-inflammatory drugs (*e.g.*, ibuprofen and celecoxib) act by inhibiting COX-2 activity. Recent research, however, has demonstrated that a class of cyclopentenone prostaglandins (cyPGs) (*e.g.*, 15-deoxy prostaglandin J2, *a.k.a.* PGJ2) plays a role in stimulating the orchestrated resolution of inflammation (*e.g.*, Rajakariar *et al.*, 2007). COX-2 is also associated with the production of cyclopentenone prostaglandins.

Consequently, inhibition of COX-2 may interfere with the full resolution of inflammation, potentially promoting the persistence of activated immune cells in tissues and leading to chronic, “smoldering” inflammation. This effect may be responsible for the increased incidence of cardiovascular disease in patients using selective COX-2 inhibitors for long
5 periods of time.

In one aspect, the compounds disclosed herein may be used to control the production of pro-inflammatory cytokines within the cell by selectively activating regulatory cysteine residues (RCRs) on proteins that regulate the activity of redox-sensitive transcription factors. Activation of RCRs by cyPGs has been shown to initiate a pro-resolution program in which the
10 activity of the antioxidant and cytoprotective transcription factor Nrf2 is potently induced and the activities of the pro-oxidant and pro-inflammatory transcription factors NF- κ B and the STATs are suppressed. In some embodiments, this increases the production of antioxidant and reductive molecules (NQO1, HO-1, SOD1, γ -GCS) and decreases oxidative stress and the production of pro-oxidant and pro-inflammatory molecules (iNOS, COX-2, TNF- α). In some
15 embodiments, the compounds of this invention may cause the cells that host the inflammatory event to revert to a non-inflammatory state by promoting the resolution of inflammation and limiting excessive tissue damage to the host.

V. Pharmaceutical Formulations and Routes of Administration

The compounds of the present disclosure may be administered by a variety of
20 methods, *e.g.*, orally or by injection (*e.g.* subcutaneous, intravenous, intraperitoneal, *etc.*). Depending on the route of administration, the active compounds may be coated in a material to protect the compound from the action of acids and other natural conditions which may inactivate the compound. They may also be administered by continuous perfusion/infusion of a disease or wound site.

To administer the therapeutic compound by other than parenteral administration, it
25 may be necessary to coat the compound with, or co-administer the compound with, a material to prevent its inactivation. For example, the therapeutic compound may be administered to a patient in an appropriate carrier, for example, liposomes, or a diluent. Pharmaceutically acceptable diluents include saline and aqueous buffer solutions. Liposomes include water-in-oil-in-water CGF emulsions as well as conventional liposomes (Strejan *et al.*, 1984).
30

The therapeutic compound may also be administered parenterally, intraperitoneally, intraspinally, or intracerebrally. Dispersions can be prepared in glycerol, liquid polyethylene

glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations may contain a preservative to prevent the growth of microorganisms.

Pharmaceutical compositions suitable for injectable use include: sterile aqueous solutions (where water soluble), dispersions, and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. See for example U.S. Patent Application by J. Zhang, entitled "Amorphous Solid Dispersions of CDDO-Me for Delayed Release Oral Dosage Compositions," filed February 13, 2009, which is incorporated herein by reference. In all cases, the composition must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (such as, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, sodium chloride, or polyalcohols such as mannitol and sorbitol, in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate or gelatin.

Sterile injectable solutions can be prepared by incorporating the therapeutic compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the therapeutic compound into a sterile carrier which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient (*i.e.*, the therapeutic compound) plus any additional desired ingredient from a previously sterile-filtered solution thereof.

The therapeutic compound can be orally administered, for example, with an inert diluent or an assimilable edible carrier. The therapeutic compound and other ingredients may also be enclosed in a hard or soft shell gelatin capsule, compressed into tablets, or incorporated directly into the subject's diet. For oral therapeutic administration, the

therapeutic compound may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. The percentage of the therapeutic compound in the compositions and preparations may, of course, be varied. The amount of the therapeutic compound in such therapeutically useful compositions is such that a suitable dosage will be obtained.

It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subjects to be treated; each unit containing a predetermined quantity of therapeutic compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the therapeutic compound and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such a therapeutic compound for the treatment of a selected condition in a patient.

The therapeutic compound may also be administered topically to the skin, eye, or mucosa. Alternatively, if local delivery to the lungs is desired the therapeutic compound may be administered by inhalation in a dry-powder or aerosol formulation.

Active compounds are administered at a therapeutically effective dosage sufficient to treat a condition associated with a condition in a patient. For example, the efficacy of a compound can be evaluated in an animal model system that may be predictive of efficacy in treating the disease in humans, such as the model systems shown in the examples and drawings.

The actual dosage amount of a compound of the present disclosure or composition comprising a compound of the present disclosure administered to a subject may be determined by physical and physiological factors such as age, sex, body weight, severity of condition, the type of disease being treated, previous or concurrent therapeutic interventions, idiopathy of the subject and on the route of administration. These factors may be determined by a skilled artisan. The practitioner responsible for administration will typically determine the concentration of active ingredient(s) in a composition and appropriate dose(s) for the individual subject. The dosage may be adjusted by the individual physician in the event of any complication.

An effective amount typically will vary from about 0.001 mg/kg to about 1000 mg/kg, from about 0.01 mg/kg to about 750 mg/kg, from about 100 mg/kg to about 500 mg/kg, from about 1.0 mg/kg to about 250 mg/kg, from about 10.0 mg/kg to about 150 mg/kg in one or

more dose administrations daily, for one or several days (depending of course of the mode of administration and the factors discussed above). Other suitable dose ranges include 1 mg to 10000 mg per day, 100 mg to 10000 mg per day, 500 mg to 10000 mg per day, and 500 mg to 1000 mg per day. In some particular embodiments, the amount is less than 10,000 mg per day with a range of 750 mg to 9000 mg per day.

The effective amount may be less than 1 mg/kg/day, less than 500 mg/kg/day, less than 250 mg/kg/day, less than 100 mg/kg/day, less than 50 mg/kg/day, less than 25 mg/kg/day or less than 10 mg/kg/day. It may alternatively be in the range of 1 mg/kg/day to 200 mg/kg/day. For example, regarding treatment of diabetic patients, the unit dosage may be an amount that reduces blood glucose by at least 40% as compared to an untreated subject. In another embodiment, the unit dosage is an amount that reduces blood glucose to a level that is $\pm 10\%$ of the blood glucose level of a non-diabetic subject.

In other non-limiting examples, a dose may also comprise from about 1 microgram/kg/body weight, about 5 microgram/kg/body weight, about 10 microgram/kg/body weight, about 50 microgram/kg/body weight, about 100 microgram/kg/body weight, about 200 microgram/kg/body weight, about 350 microgram/kg/body weight, about 500 microgram/kg/body weight, about 1 milligram/kg/body weight, about 5 milligram/kg/body weight, about 10 milligram/kg/body weight, about 50 milligram/kg/body weight, about 100 milligram/kg/body weight, about 200 milligram/kg/body weight, about 350 milligram/kg/body weight, about 500 milligram/kg/body weight, to about 1000 mg/kg/body weight or more per administration, and any range derivable therein. In non-limiting examples of a derivable range from the numbers listed herein, a range of about 5 mg/kg/body weight to about 100 mg/kg/body weight, about 5 microgram/kg/body weight to about 500 milligram/kg/body weight, *etc.*, can be administered, based on the numbers described above.

In certain embodiments, a pharmaceutical composition of the present disclosure may comprise, for example, at least about 0.1% of a compound of the present disclosure. In other embodiments, the compound of the present disclosure may comprise between about 2% to about 75% of the weight of the unit, or between about 25% to about 60%, for example, and any range derivable therein.

Single or multiple doses of the agents are contemplated. Desired time intervals for delivery of multiple doses can be determined by one of ordinary skill in the art employing no more than routine experimentation. As an example, subjects may be administered two doses daily at approximately 12 hour intervals. In some embodiments, the agent is administered once a day.

The agent(s) may be administered on a routine schedule. As used herein a routine schedule refers to a predetermined designated period of time. The routine schedule may encompass periods of time which are identical or which differ in length, as long as the schedule is predetermined. For instance, the routine schedule may involve administration
5 twice a day, every day, every two days, every three days, every four days, every five days, every six days, a weekly basis, a monthly basis or any set number of days or weeks therebetween. Alternatively, the predetermined routine schedule may involve administration on a twice daily basis for the first week, followed by a daily basis for several months, *etc.* In other
10 embodiments, the invention provides that the agent(s) may be taken orally and that the timing of which is or is not dependent upon food intake. Thus, for example, the agent can be taken every morning and/or every evening, regardless of when the subject has eaten or will eat.

VI. Combination Therapy

In addition to being used as a monotherapy, the compounds of the present invention may also find use in combination therapies. Effective combination therapy may be achieved
15 with a single composition or pharmacological formulation that includes both agents, or with two distinct compositions or formulations, administered at the same time, wherein one composition includes a compound of this invention, and the other includes the second agent(s). Alternatively, the therapy may precede or follow the other agent treatment by intervals ranging from minutes to months.

20 Non-limiting examples of such combination therapy include combination of one or more compounds of the invention with another anti-inflammatory agent, a chemotherapeutic agent, radiation therapy, an antidepressant, an antipsychotic agent, an anticonvulsant, a mood stabilizer, an anti-infective agent, an antihypertensive agent, a cholesterol-lowering agent or other modulator of blood lipids, an agent for promoting weight loss, an antithrombotic agent,
25 an agent for treating or preventing cardiovascular events such as myocardial infarction or stroke, an antidiabetic agent, an agent for reducing transplant rejection or graft-versus-host disease, an anti-arthritic agent, an analgesic agent, an anti-asthmatic agent or other treatment for respiratory diseases, or an agent for treatment or prevention of skin disorders. Compounds of the invention may be combined with agents designed to improve a patient's
30 immune response to cancer, including (but not limited to) cancer vaccines. See Lu *et al.* (2011), which is incorporated herein by reference.

VII. Examples

The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.

Methods and Materials

Nitric Oxide Production and Cell Viability Assay. RAW264.7 mouse macrophages were plated in 96-well plates at 30,000 cells/well in triplicate in RPMI1640 + 0.5% FBS and incubated at 37°C with 5% CO₂. On the next day, cells were pre-treated with DMSO or drug (0-200nM dose range) for 2 hours, and then treated with recombinant mouse IFN γ (R&D Systems) for 24 hours. Nitric Oxide concentration in media was determined using the Griess reagent system (Promega). Cell viability was determined using WST-1 reagent (Roche). IC₅₀ values were determined based on the suppression of IFN γ induced Nitric Oxide production normalized to cell viability.

NQO1-ARE Luciferase Reporter Assay. This assay allows for quantitative assessment of the endogenous activity of the Nrf2 transcription factor in cultured mammalian cells. Expression of *Firefly* luciferase from NQO1-ARE luciferase reporter plasmid is controlled by binding of Nrf2 to a specific enhancer sequence corresponding to the antioxidant response element (ARE) that was identified in the promoter region of the human NADPH:quinone oxidoreductase 1 (*NQO1*) gene (Xie *et al.*, 1995). The plasmid was constructed by inserting a sequence:


5'- CAGTCACAGTGACTCAGCAGAATCTG-3' (SEQ ID NO:1)

encompassing the human NQO1-ARE into the pLuc-MCS vector using HindIII/XhoI cloning sites (GenScript Corp., Piscataway, NJ). The assay is performed in HuH7 cells maintained in DMEM (Invitrogen) supplemented with 10% FBS and 100 U/ml (each) of penicillin and streptomycin. For the assay, cells are plated in 96-well plates at 17,000 cells per well. Twenty four hours later, the cells are co-transfected with 50 ng each of NQO1-ARE reporter plasmid and pRL-TK plasmid using Lipofectamine 2000 transfection reagent (Invitrogen).


pRL-TK plasmid constitutively expresses *Renilla* luciferase and is used as an internal control for normalization of transfection levels. Thirty hours after transfection, the cells are treated with compounds (at concentrations ranging from 0 to 1 μ M) for eighteen hours. *Firefly* and *Renilla* luciferase activity is assayed by Dual-Glo Luciferase Assay (Promega Corp.,
5 Madison, WI), the luminescence signal is measured on an L-Max II luminometer (Molecular Devices). *Firefly* luciferase activity is normalized to the *Renilla* activity, and fold induction over a vehicle control (DMSO) of normalized *Firefly* activity is calculated. The fold induction at 62.5 nM concentration is used for comparing relative potencies of compounds to induce Nrf2 transcriptional activity. See Xie *et al.*, 1995, which is incorporated herein by
10 reference.

Scheme 1a

Synthetic Schemes, Reagents and Yields




Scheme 1b




Reagents and conditions: (a) LiAlH_4 , THF, 0 °C to rt, 72%; (b) $\text{PhI}(\text{OAc})_2$, TEMPO, H_2O , CH_2Cl_2 , rt, 72%; (c) triethyl phosphonoacetate, NaH , 0 °C to rt, 67%; (d) TPAP, NMO, 4 Å MS, CH_2Cl_2 , rt, 88%; (e) H_2 , Pd/C, THF, rt, 99%; (f) EtOCHO , NaOMe, MeOH, rt; (g) i) $\text{NH}_2\text{OH}\cdot\text{HCl}$, EtOH, H_2O , 55 °C, ii) MeOH, HCl, rt, 80% from **5**; (h) NaOMe, MeOH, 55 °C, 99%; (i) i) DBDMH, DMF, 0 °C, ii) pyridine, 55 °C, **TX63762**: 17%, **TX63742**: 75%; (j) HCl, H_2O , MeCN, 65 °C, 98%.

Scheme 2




Reagents and conditions: (a) HCO_2Et , NaOMe, MeOH, rt; (b) $\text{NH}_2\text{OH}\cdot\text{HCl}$, EtOH, H_2O , 55°C , 81% from 5; (c) NaOMe, MeOH, 55°C , quantitative; (d) i) DBDMH, DMF, 0°C , ii) pyridine, 55°C , 63% from 11a, 11b.

Scheme 3




Reagents and conditions: (a) ROH, HCl, rt to 55 °C, TX64042: 65%, TX64043: 79%, TX64058: 75%.

Scheme 4




Reagents and conditions: (a) ROH, TEA, DMAP, EDCl, CH₂Cl₂, rt, TX64046: 64%, TX64066: 64%, TX64067: 15%, TX64053: 70%; (b) HCl, CH₂Cl₂, 1,4-dioxane, rt, 83%.

Scheme 5




Reagents and conditions: (a) amine, TEA, DMAP, CH₂Cl₂, rt, TX64064: 22%, TX64065: 29%, TX64057: 32%, TX64059: 71%, TX64075: 25%, TX63949: 47%, TX63763: 82%, TX64045: 45%, TX64048: 51%, TX64068: 12%, TX64124: 88%; (b) amine·HCl, TEA, DMAP, EDCl, CH₂Cl₂, rt, TX64056: 57%, TX64056: 81%, TX63768: 70%, TX63764: 76%, TX64060: 77%, TX63950: 71%, TX64049: 59%, TX64047: 46%, TX64044: 65%, TX64052: 64%; (c) HCl, H₂O, MeCN, 55 °C, 71%; (d) HCl, 1,4-dioxane, CH₂Cl₂, rt, 35%.

Scheme 6




Reagents and conditions: (a) NH₄Cl, EDCI, HOBT·xH₂O, DIEA, DMF, rt, 49%.

Scheme 7




Reagents and conditions: (a) H_2 , Pd/C, EtOAc, CH_2Cl_2 , rt; (b) HBr, Br₂, MeCN, 35 °C; (c) NaOMe, MeOH, 50 °C; (d) i) DBDMH, DMF, 0 °C, ii) pyridine, 55 °C, 65% from **13**.

Scheme 8




Reagents and conditions: (a) CDI, MeCN, reflux, 5 h, 75%.

Scheme 9




Reagents and conditions: (a) 4-morpholinecarbonyl chloride, DMAP, pyridine, rt to 90 °C, 18 h, 49%.

Scheme 10




Reagents and conditions: (a) 1-pyrrolidinecarbonyl chloride, DMAP, pyridine, rt to 90 °C, 18 h, 35%.

Scheme 11




Reagents and conditions: (a) ethyl isocyanate, toluene, rt to 90 °C, 16 h, 85%.

Scheme 12a



Scheme 12b




Reagents and conditions: (a) LiAlH_4 , THF, 0°C to reflux; (b) NaOCl , NaHCO_3 , NaBr , TEMPO , H_2O , CH_2Cl_2 , 0°C to rt, 79% from oleanolic acid; (c) i) KO^tBu , (methoxymethyl)triphenylphosphonium chloride, THF, rt, ii) H_2SO_4 , rt, 96%; (d) NaBH_4 , MeOH , THF, rt, quantitative; (e) Ac_2O , pyridine, DMAP, CH_2Cl_2 , rt, 75% from 19; (f) AcOOH , Na_2CO_3 , AcOH , 50°C , 96%; (g) Br_2 , HCl , 1,4-dioxane, MeCN , 35°C ; (h)

{00086504}


H₂SO₄, MeOH, THF, 35 °C to reflux, 74% from **22**; (i) NaOCl, AcOH, H₂O, rt, 80%; (j) NaOMe, MeOH, EtOCHO, 0 °C to rt; (k) NH₂OH·HCl, EtOH, H₂O, 55 °C; (l) i) NaOMe, MeOH, 55 °C, ii) HCl, 1,4-dioxane, 55 °C, 71% from **25**; (m) i) DBDMH, DMF, 0 °C, ii) pyridine, 55 °C, 80%; (n) MeOTf, 2,6-di-*tert*-butyl-4-methylpyridine, CH₂Cl₂, rt, 76%.

Scheme 13




Reagents and conditions: (a) Ac₂O, pyridine, DMAP, CH₂Cl₂, rt, 76%.

Scheme 14




Reagents and conditions: (a) EtNCO, toluene, rt to 70 °C, 73%.

Scheme 15



Reagents and conditions: (a) DIBAL-H, THF, 0 °C to rt, quantitative; (b) NBS, DME, H₂O, rt, quantitative; (c) NaOMe, MeOH, 55 °C, 32%; (d) i) DBDMMH, DMF, 0 °C, ii) pyridine, 55 °C, 58%.

Scheme 16



Reagents and conditions: (a) EtNCO, toluene, 70 °C, 75%.

Synthesis and Characterization of Compounds and Intermediates

Compound 2: LiAlH₄ (2.0 M in THF, 50 mL, 100 mmol) was carefully added to a 0 °C solution of compound 1 (9.65 g, 20.0 mmol) in THF (350 mL) over ~10 min. The ice bath was removed after 30 min and the reaction stirred an additional 2.5 h. The solution was diluted with MTBE (200 mL); cooled to 0 °C; and quenched by sequential addition of 5.3 mL each water, 4 M NaOH, and water. The mixture was stirred at room temperature for 30 min, filtered through a plug of celite, eluted with MTBE, and concentrated to give a white solid. The resultant solid was suspended in CH₂Cl₂, stirred at room temperature for 2 h, and the solid isolated by filtration [washed with CH₂Cl₂, then dried] to give compound 1 (6.56 g, 72%) which was used without further purification: *m/z* 441.3 (M-H₂O+1).

Compound 3: PhI(OAc)₂ (10.40 g, 32.3 mmol), TEMPO (2.27 g, 14.5 mmol), and water (15 mL) were added to a room temperature suspension of compound 2 (6.56 g, 14.3 mmol) in CH₂Cl₂ (1.5 L) and stirred vigorously for 18 h. The resultant biphasic, homogeneous solution was treated with anhydrous Na₂SO₄, stirred an additional 15 min, filtered and concentrated to a viscous oil. The residue was purified by flash chromatography (silica gel, 0% to 100% EtOAc in hexanes) to give compound 4 (4.72 g, 72%) as an off-white solid: *m/z* 439.3 (M-H₂O+1).

Compound 4: Triethyl phosphonoacetate (18.8 mL, 94.8 mmol) was added to a 0 °C suspension of NaH (3.81 g, 60%, 95.3 mmol) in THF (285 mL), and the resultant mixture stirred at 0 °C for 15 min, then warmed to room temperature over 30 min. The mixture was cooled to 0 °C, a solution of compound 3 (8.67 g, 19.0 mmol) in THF (75 mL) was added, and the transfer completed with THF (20 mL) wash. The reaction was maintained at 0 °C for approximately 4 h and then warmed to room temperature overnight. The reaction was again cooled to 0 °C and quenched by the careful addition of 1 N HCl, stirred vigorously at room temperature for 15 min, and extracted with MTBE. The combined organic fractions were washed with brine, then dried over Na₂SO₄, and concentrated. The residue was purified by flash chromatography (silica gel, 0% to 100% EtOAc in hexanes) to give compound 4 (6.68 g, 67%) as a white solid: *m/z* 509.3 (M-H₂O+1).

Compound 5: A mixture of compound 4 (6.68 g, 12.7 mmol), 4 Å MS (12.7 g), NMO (4.47 g, 38.2 mmol), and CH₂Cl₂ (250 mL) was stirred at room temperature for 15 min. TPAP (458 mg, 1.30 mmol) was then added, and the reaction was stirred for 1 h. The reaction was concentrated to ~10 mL and purified by flash chromatography (silica gel, 0% to

100% EtOAc in hexanes) to give compound **5** (5.89 g, 88%) as a white foam solid: m/z 523.3 (M+1).

Compound 6: A flask containing a suspension of compound **5** (5.89 g, 11.3 mmol), Pd/C (10%, 1.45 g), and THF (250 mL) was purged with N₂ and then H₂, and the reaction
5 was vigorously stirred under H₂ (balloon pressure) for 5 h. The resultant suspension was sparged with N₂ for 30 min, filtered through a short plug of celite, eluted with CH₂Cl₂, and concentrated to give compound **6** (5.84 g, 99%) as a white solid: m/z 525.4 (M+1).

Compounds 7a,7b: A solution of compound **6** (5.84 g, 11.1 mmol), NaOMe (25 % in MeOH, 35 mL) and HCO₂Et (70 mL) was stirred at room temperature for 3 h, diluted with
10 1 N HCl, and extracted with EtOAc. The combined organic fractions were washed with brine, dried with Na₂SO₄, and concentrated to give compounds **7a,b** (Me-ester:Et-ester = 9:91) as an off-white foam solid that was used without further purification: **7a** m/z 539.3 (M+1), **7b** m/z 553.4 (M+1).

Compound 8a, 8b: A mixture of compounds **7a, 7b** (all above obtained, ~11.3 mmol), NH₂OH·HCl (1.06 g, 15.3 mmol), EtOH (100 mL) and water (17 mL) was
15 heated to 55 °C for 16 h. The resultant solution was cooled to room temperature, diluted with 1 N HCl and extracted with EtOAc. The combined organic fractions were washed with 1 N HCl and brine, dried with Na₂SO₄, and concentrated. The residue was dissolved in MeOH (700 mL), treated with 12 N HCl (1.0 mL), and stirred at room temperature for 5 h. The
20 mixture was concentrated to ~30 mL, diluted with CH₂Cl₂, washed with brine, dried with Na₂SO₄ and concentrated. The residue was purified by flash chromatography (silica gel, 0% to 60% EtOAc in hexanes) to give compounds **8a, 8b** (4.84 g, Me-ester:Et-ester = 25:75, 80% from **6**) as a white solid: **8a** m/z 536.4 (M+1), **8b** m/z 550.3 (M+1).

Compounds 9a, 9b: A solution of **8a, 8b** (4.84 g, 8.84 mmol), NaOMe (25% in MeOH, 5.3 mL), and MeOH (110 mL) was heated to 55 °C for 5 h. The resultant mixture
25 was diluted with 1 N HCl and extracted with CH₂Cl₂. The combined organic fractions were washed with brine, dried with Na₂SO₄, and concentrated to give compounds **9a, 9b** (4.69 g, carboxylic acid:Me-ester = 17:83, 99%) as a yellow solid that was used without further purification: **9a** m/z 522.3 (M+1), **9b** m/z 536.3 (M+1).

Compounds TX63762 and TX63742: 1,3-dibromo-5,5-dimethylhydantoin (1.25 g, 4.37 mmol) was added to a 0 °C solution of **9a, 9b** (4.69 g, 8.79 mmol) in DMF (106 mL). The mixture was stirred at 0 °C for 4 h. Pyridine (2.83 mL, 35.0 mmol) was then added, and the reaction was heated to 55 °C. The reaction was cooled to room temperature after 4 h and was stirred an additional 3 d. The resultant solution was diluted with 1 N HCl and extracted
30

with EtOAc. The combined organic fractions were washed with water and brine, dried with Na₂SO₄, and concentrated. The residue was purified by flash chromatography (silica gel, 0% to 100% EtOAc in hexanes) to give compound **TX63762** (780 mg, 17%) as a white solid and compound **TX63742** (3.53 g, 75%) as an off-white solid: **TX63762** ¹H NMR (400 MHz, CDCl₃) δ 8.04 (s, 1H), 5.98 (s, 1H), 3.06 (d, 1H, *J* = 4.7 Hz), 2.34 (m, 2H), 2.24 (td, 1H, *J* = 4.3, 13.4 Hz), 1.69 (m, 11H), 1.50 (s, 3H), 1.49 (s, 3H), 1.26 (s, 3H), 1.26 (m, 4H), 1.18 (s, 3H), 1.04 (m, 2H), 1.02 (s, 3H), 0.93 (s, 3H), 0.88 (s, 3H); *m/z* 520.3 (M+1); **TX63742** ¹H NMR (400 MHz, CDCl₃) δ 8.04 (s, 1H), 5.97 (s, 1H), 3.67 (s, 3H), 3.06 (d, 1H, *J* = 4.7 Hz), 2.30 (m, 2H), 2.21 (td, 1H, *J* = 4.6, 13.0 Hz), 1.74 (m, 9H), 1.50 (s, 6H), 1.46 (m, 2H), 1.26 (s, 3H), 1.25 (m, 4H), 1.18 (s, 3H), 1.02 (m, 2H), 1.01 (s, 3H), 0.92 (s, 3H), 0.87 (s, 3H); *m/z* 534.3 (M+1).

Compound TX63762: A suspension of **TX63742** (3.53 g, 6.61 mmol) in MeCN (200 mL) and 1 N HCl (66 mL) was heated to 65 °C for 17 h. The resultant solution was cooled to room temperature and extracted with EtOAc. The combined organic fractions were washed with brine, dried with Na₂SO₄, and concentrated to give compound **TX63762** (3.354 g, 98%) as a pale yellow solid.

Compounds 10a, 10b: A solution of compound **5** (250 mg, 0.478 mmol), NaOMe (25 % in MeOH, 1.25 mL) and HCO₂Et (3.75 mL) was stirred at room temperature for 3 h, diluted with EtOAc, washed with 1 N HCl and brine, dried with Na₂SO₄, and concentrated to give compounds **10a, 10b** (Me-ester:Et-ester = 23:77) as an off-white foam solid that were used without further purification: **10a** *m/z* 537.3 (M+1), **10b** *m/z* 551.4 (M+1).

Compounds 11a, 11b: A mixture of compounds **10a, 10b** (all above obtained, ~0.48 mmol), NH₂OH·HCl (45.1 g, 0.649 mmol), EtOH (4.25 mL) and water (0.75 mL) was heated to 55 °C for 20 h. The resultant solution was cooled to room temperature, diluted with EtOAc, washed with 1 N HCl and brine, dried with Na₂SO₄, and concentrated. The crude residue was purified by flash chromatography (silica gel, 0% to 60% EtOAc in hexanes) to give compounds **11a, 11b** (210 mg, Me-ester:Et-ester = 21:79, 81% from **5**) as a white solid: **11a** *m/z* 534.3 (M+1), **11b** *m/z* 548.3 (M+1).

Compound 12: A mixture of compounds **11a, 11b** (210 mg, 0.385 mmol), NaOMe (25% in MeOH, 0.2 mL) and MeOH (4.8 mL) was heated to 55 °C for 3.5 h. The resultant mixture was diluted with 1 N HCl and extracted with EtOAc. The combined organic fractions were dried with Na₂SO₄ and concentrated to give compound **12** (206 mg,

quantitative) as a glassy, white solid that was used without further purification: m/z 534.3 (M+1).

Compounds TX63743: 1,3-dibromo-5,5-dimethylhydantoin (57.6 mg, 0.201 mmol) was added to a 0 °C solution of compound **12** (206 mg, ~0.385 mmol) in DMF (3.9 mL).
5 The mixture was stirred at 0 °C for 2 h, pyridine (0.13 mL, 1.6 mmol) was added, and the reaction heated to 55 °C. The reaction was cooled to room temperature after 4 h and stirred overnight. The resultant solution was diluted with EtOAc, washed with 1 N HCl, 10% Na₂SO₃, and brine, then dried with Na₂SO₄ and concentrated. The crude residue was purified by flash chromatography (silica gel, 0% to 45% EtOAc in hexanes) to give compound
10 **TX63743** (129 mg, 63% from **11a**, **11b**) as a white solid: ¹H NMR (400 MHz, CDCl₃) δ 8.02 (s, 1H), 6.95 (d, 1H, J = 16.3 Hz), 5.97 (s, 1H), 5.87 (d, 1H, J = 16.4 Hz), 3.74 (s, 3H), 2.85 (d, 1H, J = 4.6 Hz), 2.57 (td, 1H, J = 4.1, 13.2 Hz), 2.06 (dt, 1H, J = 4.0, 13.8 Hz), 1.65 (m, 8H), 1.47 (s, 3H), 1.32 (s, 3H), 1.25 (s, 3H), 1.20 (m, 6H), 1.17 (s, 3H), 1.01 (s, 3H), 0.98 (s, 3H), 0.91 (s, 3H); m/z 532.3 (M+1).

15 **Compound TX64042:** A mixture of **TX63762** (53.0 mg, 0.102 mmol), EtOH (2 mL) and 12 N HCl (2 drops) was stirred at room temperature for 21 h, then at 50 °C for 5 h. The resultant suspension was diluted with EtOAc to give a homogeneous solution that was washed with brine, dried with Na₂SO₄, and concentrated. The residue was purified by flash chromatography (silica gel, 0% to 100% EtOAc in hexanes) to give compound **TX64042**
20 (36.5 mg, 65%) as a white solid: ¹H NMR (400 MHz, CDCl₃) δ 8.04 (s, 1H), 5.97 (s, 1H), 4.14 (d, 1H, J = 7.1 Hz), 4.10 (d, 1H, J = 7.1 Hz), 3.07 (d, 1H, J = 4.7 Hz), 2.27 (m, 3H), 1.68 (m, 11H), 1.50 (s, 6H), 1.26 (s, 3H), 1.26 (t, 3H, J = 7.1 Hz), 1.24 (m, 4H), 1.18 (s, 3H), 1.01 (m, 2H), 1.01 (s, 3H), 0.93 (s, 3H), 0.88 (s, 3H); m/z 548.3 (M+1).

Compound TX64043: A mixture of **TX63762** (52.4 mg, 0.101 mmol), *i*-PrOH (2
25 mL) and 12 N HCl (2 drops) was stirred at room temperature for 21 h, then at 50 °C overnight. The resultant suspension was diluted with EtOAc to give a homogeneous solution that was washed with 1 N HCl and brine, dried with Na₂SO₄, and concentrated. The residue was purified by flash chromatography (silica gel, 0% to 100% EtOAc in hexanes) to give compound **TX64043** (44.8 mg, 79%) as a white solid: ¹H NMR (400 MHz, CDCl₃) δ 8.04 (s,
30 1H), 5.97 (s, 1H), 4.99 (sept, 1H, J = 6.3 Hz), 3.08 (d, 1H, J = 4.7 Hz), 2.24 (m, 3H), 1.73 (m, 10 H), 1.50 (s, 6H), 1.43 (m, 1H), 1.26 (m, 3H), 1.22 (m, 10H), 1.18 (s, 3H), 1.03 (m, 2H), 1.01 (s, 3H), 0.93 (s, 3H), 0.88 (s, 3H); m/z 562.3 (M+1).

Compound TX64058: A mixture of **TX63762** (40.0 mg, 0.0770 mmol), *c*-HexOH (2 mL) and 37% HCl (2 drops) was stirred at 55 °C for 21 h. The resultant suspension was diluted with EtOAc to give a homogeneous solution that was washed with water and brine, dried with Na₂SO₄, and concentrated. The residue was purified by flash chromatography (silica gel, 0% to 100% EtOAc in hexanes) to give compound **TX64058** (34.8 mg, 75%) as a white solid: ¹H NMR (400 MHz, CDCl₃) δ 8.04 (s, 1H), 5.97 (s, 1H), 4.73 (m, 1H), 3.08 (d, 1H, *J* = 4.7 Hz), 2.26 (m, 3H), 1.77 (m, 12H), 1.55 (s, 3H), 1.50 (s, 3H), 1.32 (m, 13H), 1.26 (s, 3H), 1.18 (s, 3H), 1.03 (m, 2H), 1.01 (s, 3H), 0.93 (s, 3H), 0.88 (s, 3H); *m/z* 602.4 (M+1).

Compound TX64046: A mixture of compound **TX63762** (39.0 mg, 0.0750 mmol), TEA (0.03 mL, 0.2 mmol), DMAP (18.1 mg, 0.148 mmol), phenol (22.5 mg, 0.239 mmol) and CH₂Cl₂ (2 mL) was stirred at room temperature for 30 min. EDCI (31.6 mg, 0.165 mmol) was added, and the reaction was stirred at room temperature for 18 h. The resultant mixture was diluted with EtOAc, washed with 1 N HCl and brine, dried with Na₂SO₄, and concentrated. The residue was purified by flash chromatography (silica gel, 0% to 100% EtOAc in hexanes) to give compound **TX64046** (28.5 mg, 64%) as a white solid: ¹H NMR (400 MHz, CDCl₃) δ 8.04 (s, 1H), 7.38 (t, 2H, *J* = 7.8 Hz), 7.23 (t, 1H, *J* = 7.4 Hz), 7.07 (m, 2H), 5.98 (s, 1H), 3.11 (d, 1H, *J* = 4.7 Hz), 2.56 (m, 2H), 2.29 (td, 1H, *J* = 4.7, 13.0 Hz), 1.77 (m, 11H), 1.49 (s, 6H), 1.28 (m, 4H), 1.26 (s, 3H), 1.17 (s, 3H), 1.08 (m, 2H), 1.03 (s, 3H), 0.96 (s, 3H), 0.90 (s, 3H); *m/z* 596.3 (M+1).

Compound TX64066: A mixture of compound **TX63762** (53.8 mg, 0.104 mmol), TEA (0.05 mL, 0.4 mmol), DMAP (37.2 mg, 0.304 mmol), benzyl alcohol (0.06 mL, 0.7 mmol) and CH₂Cl₂ (2 mL) was stirred at room temperature for 15 min. EDCI (59.8 mg, 0.312 mmol) was added, and the reaction was stirred at room temperature for 17 h. The resultant mixture was diluted with EtOAc, washed with 1 N HCl and brine, dried with Na₂SO₄, and concentrated. The residue was purified by flash chromatography (silica gel, 0% to 100% EtOAc in hexanes) to give compound **TX64066** (40.5 mg, 64%) as a white solid: ¹H NMR (400 MHz, CDCl₃) δ 8.03 (s, 1H), 7.35 (m, 5H), 5.97 (s, 1H), 5.12 (d, 1H, *J* = 12.3 Hz), 5.09 (d, 1H, *J* = 12.3 Hz), 3.05 (d, 1H, *J* = 4.7 Hz), 2.35 (m, 2H), 2.23 (td, 1H, *J* = 4.7, 13.1 Hz), 1.80 (m, 7H), 1.50 (m, 4H), 1.49 (s, 3H), 1.44 (s, 3H), 1.26 (s, 3H), 1.21 (m, 4H), 1.18 (s, 3H), 1.01 (m, 2H), 1.00 (s, 3H), 0.91 (s, 3H), 0.87 (s, 3H); *m/z* 610.3 (M+1).

Compound TX64067: A mixture of compound **TX63762** (51.6 mg, 0.0993 mmol), TEA (0.05 mL, 0.4 mmol), DMAP (38.8 mg, 0.318 mmol), *t*-BuOH (0.10 mL, 1.0 mmol) and CH₂Cl₂ (2 mL) was stirred at room temperature for 15 min. EDCI (60.7 mg, 0.317 mmol)

was added, and the reaction was stirred at room temperature for 17 h. The resultant mixture was diluted with EtOAc, washed with 1 N HCl and brine, dried with Na₂SO₄, and concentrated. The residue was purified by flash chromatography (silica gel, 0% to 100% EtOAc in hexanes), then purified by additional flash chromatography (C₁₈ silica gel, 0% to 100% MeCN in water) to give compound **TX64067** (8.3 mg, 15%) as a white solid: ¹H NMR (400 MHz, CDCl₃) δ 8.04 (s, 1H), 5.97 (s, 1H), 3.07 (d, 1H, *J* = 4.7 Hz), 2.18 (m, 3H), 1.79 (m, 6H), 1.51 (s, 3H), 1.51 (m, 6H), 1.50 (s, 3H), 1.44 (s, 9H), 1.26 (s, 3H), 1.24 (m, 3H), 1.18 (s, 3H), 1.02 (m, 2H), 1.01 (s, 3H), 0.93 (s, 3H), 0.87 (s, 3H); *m/z* 520.3 (M-*t*-Bu+H+1).

Compound TX64053: A mixture of compound **TX63762** (70 mg, 0.14 mmol), TEA (0.06 mL, 0.4 mmol), DMAP (52.9 mg, 0.433 mmol), 1-Boc-4-hydroxypiperidine (53.8 mg, 0.267 mmol) and CH₂Cl₂ (3 mL) was stirred at room temperature for 15 min. EDCI (78.1 mg, 0.407 mmol) was added, and the reaction was stirred at room temperature for 17 h. The resultant mixture was diluted with EtOAc, washed with 1 N HCl and brine, dried with Na₂SO₄, and concentrated. The residue was purified by flash chromatography (silica gel, 0% to 100% EtOAc in hexanes) to give compound **TX64053** (68.7 mg, 70%) as a white solid: ¹H NMR (400 MHz, CDCl₃) δ 8.04 (s, 1H), 5.98 (s, 1H), 4.90 (m, 1H), 3.72 (m, 2H), 3.21 (m, 2H), 3.06 (d, 1H, *J* = 4.6 Hz), 2.27 (m, 3H), 1.68 (m, 15H), 1.50 (s, 6H), 1.46 (s, 9H), 1.26 (s, 3H), 1.25 (m, 4H), 1.18 (s, 3H), 1.04 (m, 2H), 1.01 (s, 3H), 0.93 (s, 3H), 0.88 (s, 3H); *m/z* 603.4 (M-Boc+H+1).

Compound TX64055: A mixture of **TX64053** (21.5 mg, 0.0306 mmol), 4 N HCl in 1,4-dioxane (0.1 mL, 0.4 mmol) and CH₂Cl₂ (0.9 mL) was stirred at room temperature for 5 h and cooled to -20 °C overnight. The resultant mixture was diluted with EtOAc, washed with brine, dried with Na₂SO₄, and concentrated to give compound **TX64055** (15.4 mg, 83%) as a white solid: ¹H NMR (400 MHz, CDCl₃) δ 8.04 (s, 1H), 5.98 (s, 1H), 4.83 (tt, 1H, *J* = 4.2, 9.0 Hz), 3.07 (d, 1H, *J* = 4.9 Hz), 3.05 (m, 1H), 2.71 (m, 2H), 2.27 (m, 3H), 1.69 (m, 17H), 1.50 (s, 6H), 1.26 (s, 3H), 1.25 (m, 4H), 1.18 (s, 3H), 1.03 (m, 2H), 1.01 (s, 3H), 0.93 (s, 3H), 0.88 (s, 3H); *m/z* 603.4 (M+1).

Compound TX64056: A mixture of compound **TX63762** (40.3 mg, 0.0775 mmol), TEA (0.04 mL, 0.3 mmol), DMAP (18.4 mg, 0.151 mmol), methoxyamine hydrochloride (26.6 mg, 0.318 mmol) and CH₂Cl₂ (2 mL) was stirred at room temperature for 15 min. EDCI (30.8 mg, 0.161 mmol) was added, and the reaction was stirred at room temperature for 20 h. The resultant mixture was diluted with EtOAc, washed with 1 N HCl and brine, dried with Na₂SO₄, and concentrated. The residue was purified by flash chromatography (silica

gel, 0% to 100% EtOAc in hexanes) to give compound **TX64056** (24.1 mg, 57%) as a white solid: ^1H NMR (400 MHz, CDCl_3) δ 8.04 (s, 1H), 5.97 (s, 1H), 3.76 (s, 3H), 3.09 (d, 1H, $J = 4.5$ Hz), 2.23 (m, 2H), 2.04 (m, 2H), 1.67 (m, 10H), 1.52 (s, 3H), 1.50 (s, 3H), 1.26 (s, 3H), 1.24 (m, 4H), 1.18 (s, 3H), 1.03 (m, 2H), 1.00 (s, 3H), 0.92 (s, 3H), 0.88 (s, 3H); m/z 549.3 (M+1).

Compound TX63770: A mixture of compound **TX63762** (108.4 mg, 0.209 mmol), TEA (0.06 mL, 0.4 mmol), DMAP (49.8 mg, 0.408 mmol), methylamine hydrochloride (29.3 mg, 0.434 mmol) and CH_2Cl_2 (3 mL) was stirred at room temperature. EDCI (78.4 mg, 0.409 mmol) was added, and the reaction was stirred at room temperature for 19 h. The resultant mixture was diluted with EtOAc, washed with 1 N HCl and brine, dried with Na_2SO_4 , and concentrated. The residue was purified by flash chromatography (silica gel, 0% to 100% EtOAc in hexanes) to give compound **TX63770** (90.1 mg, 81%) as a white solid: ^1H NMR (400 MHz, CDCl_3) δ 8.04 (s, 1H), 5.96 (s, 1H), 5.44 (s, 1H), 3.09 (d, 1H, $J = 4.7$ Hz), 2.80 (d, 3H, $J = 4.8$ Hz), 2.22 (td, 1H, $J = 4.3, 13.5$ Hz), 2.13 (t, 2H, $J = 8.2$ Hz), 1.67 (m, 11H), 1.53 (s, 3H), 1.50 (s, 3H), 1.26 (s, 3H), 1.24 (m, 4H), 1.18 (s, 3H), 1.02 (m, 2H), 1.00 (s, 3H), 0.92 (s, 3H), 0.87 (s, 3H); m/z 533.3 (M+1).

Compound TX63768: A mixture of compound **TX63762** (77.5 mg, 0.149 mmol), TEA (0.04 mL, 0.3 mmol), DMAP (35.5 mg, 0.291 mmol), ethylamine hydrochloride (25 mg, 0.31 mmol) and CH_2Cl_2 (2 mL) was stirred at room temperature for 30 min. EDCI (55.5 mg, 0.290 mmol) was added, and the reaction was stirred at room temperature for 17 h. The resultant mixture was diluted with CH_2Cl_2 , washed with 1 N HCl and brine, dried with Na_2SO_4 , and concentrated. The residue was purified by flash chromatography (silica gel, 0% to 100% EtOAc in hexanes) to give compound **TX63768** (56.6 mg, 70%) as a white solid: ^1H NMR (400 MHz, CDCl_3) δ 8.02 (s, 1H), 5.96 (s, 1H), 5.34 (s, 1H), 3.27 (dq, 2H, $J = 5.1, 7.1$ Hz), 3.10 (d, 1H, $J = 4.6$ Hz), 2.24 (td, 1H, $J = 4.0, 13.1$ Hz), 2.12 (t, 2H, $J = 8.1$ Hz), 1.68 (m, 11H), 1.50 (s, 3H), 1.48 (s, 3H), 1.26 (s, 3H), 1.24 (m, 4H), 1.18 (s, 3H), 1.14 (t, 3H, $J = 7.3$ Hz), 1.03 (m, 2H), 1.02 (s, 3H), 0.94 (s, 3H), 0.89 (s, 3H); m/z 547.4 (M+1).

Compound TX63764: A mixture of compound **TX63762** (75.9 mg, 0.147 mmol), TEA (0.04 mL, 0.3 mmol), DMAP (35.9 mg, 0.294 mmol), 2,2,2-trifluoroethylamine hydrochloride (39.1 mg, 0.289 mmol) and CH_2Cl_2 (2 mL) was stirred at room temperature for 10 min. EDCI (56.8 mg, 0.296 mmol) was added, and the reaction was stirred at room temperature for 17 h. The resultant mixture was diluted with CH_2Cl_2 , washed with 1 N HCl and brine, dried with Na_2SO_4 , and concentrated. The residue was purified by flash

chromatography (silica gel, 0% to 100% EtOAc in hexanes) to give compound **TX63764** (66.4 mg, 76%) as a white solid: ^1H NMR (400 MHz, CDCl_3) δ 8.03 (s, 1H), 5.98 (s, 1H), 5.65 (s, 1H), 3.91 (m, 2H), 3.07 (d, 1H, $J = 4.7$ Hz), 2.25 (m, 1H), 2.23 (t, 2H, $J = 8.1$ Hz), 1.71 (m, 11H), 1.52 (s, 3H), 1.51 (s, 3H), 1.26 (s, 3H), 1.26 (m, 4H), 1.19 (s, 3H), 1.04 (m, 2H), 1.03 (s, 3H), 0.94 (s, 3H), 0.89 (s, 3H); m/z 601.3 (M+1).

Compound TX64064: A mixture of compound **TX63762** (42.1 mg, 0.0810 mmol), TEA (0.04 mL, 0.3 mmol), DMAP (21.2 mg, 0.165 mmol), isopropylamine (0.02 mL, 0.2 mmol) and CH_2Cl_2 (2 mL) was stirred at room temperature for 20 min. EDCI (30.1 mg, 0.157 mmol) was added, and the reaction was stirred at room temperature for 16 h. Additional isopropylamine (0.05 mL, 0.6 mmol) and EDCI (50 mg, 0.26 mmol) were added, and the reaction stirred overnight at room temperature. The resultant mixture was diluted with EtOAc, washed with 1 N HCl and brine, dried with Na_2SO_4 , and concentrated. The residue was purified by flash chromatography (silica gel, 0% to 100% EtOAc in hexanes) and was then purified by additional flash chromatography (silica gel, 0% to 100% EtOAc in hexanes, each containing 0.5% TEA) to give compound **TX64064** (10.2 mg, 22%) as a white solid: ^1H NMR (400 MHz, CDCl_3) δ 8.04 (s, 1H), 5.96 (s, 1H), 5.23 (d, 1H, $J = 8.0$ Hz), 4.06 (m, 1H), 3.10 (d, 1H, $J = 4.6$ Hz), 2.22 (td, 1H, $J = 4.5, 13.1$ Hz), 2.09 (t, 2H, $J = 8.1$ Hz), 1.68 (m, 11H), 1.53 (s, 3H), 1.50 (s, 3H), 1.26 (s, 3H), 1.24 (m, 4H), 1.18 (s, 3H), 1.14 (m, 6H), 1.02 (m, 2H), 1.00 (s, 3H), 0.92 (s, 3H), 0.88 (s, 3H); m/z 561.3 (M+1).

Compound TX64065: A mixture of compound **TX63762** (50.8 mg, 0.0977 mmol), TEA (0.05 mL, 0.4 mmol), DMAP (36.7 mg, 0.300 mmol), *tert*-butylamine (0.06 mL, 0.6 mmol) and CH_2Cl_2 (2 mL) was stirred at room temperature for 15 min. EDCI (59.2 mg, 0.309 mmol) was added, and the reaction was stirred at room temperature for 17 h. The resultant mixture was diluted with EtOAc, washed with 1 N HCl and brine, dried with Na_2SO_4 , and concentrated. The residue was purified by flash chromatography (silica gel, 0% to 100% EtOAc in hexanes) to give compound **TX64065** (16.1 mg, 29%) as a white solid: ^1H NMR (400 MHz, CDCl_3) δ 8.04 (s, 1H), 5.96 (s, 1H), 5.24 (s, 1H), 3.08 (d, 1H, $J = 4.6$ Hz), 2.22 (td, 1H, $J = 4.6, 13.2$ Hz), 2.05 (t, 2H, $J = 8.1$ Hz), 1.67 (m, 11H), 1.53 (s, 3H), 1.50 (s, 3H), 1.34 (s, 9H), 1.26 (s, 3H), 1.24 (m, 4H), 1.18 (s, 3H), 1.01 (m, 2H), 1.00 (s, 3H), 0.92 (s, 3H), 0.87 (s, 3H); m/z 575.4 (M+1).

Compound TX64057: A mixture of compound **TX63762** (40.4 mg, 0.0777 mmol), TEA (0.04 mL, 0.3 mmol), DMAP (19.3 mg, 0.158 mmol), cyclohexylamine (0.04 mL, 0.4 mmol) and CH_2Cl_2 (2 mL) was stirred at room temperature for 15 min. EDCI (29.8 mg,

0.155 mmol) was added, and the reaction was stirred at room temperature for 21 h. The resultant mixture was diluted with EtOAc, washed with 1 N HCl and brine, dried with Na₂SO₄, and concentrated. The residue was purified by flash chromatography (silica gel, 0% to 100% EtOAc in hexanes) to give compound **TX64057** (14.7 mg, 32%) as a white solid: ¹H NMR (400 MHz, CDCl₃) δ 8.04 (s, 1H), 5.96 (s, 1H), 5.27 (d, 1H, *J* = 8.2 Hz), 3.74 (m, 1H), 3.10 (d, 1H, *J* = 4.6 Hz), 2.22 (td, 1H, *J* = 4.5, 13.1 Hz), 2.10 (t, 2H, *J* = 8.1 Hz), 1.45 (m, 27H), 1.52 (s, 3H), 1.50 (s, 3H), 1.26 (s, 3H), 1.18 (s, 3H), 1.00 (s, 3H), 0.92 (s, 3H), 0.88 (s, 3H); *m/z* 601.4 (M+1).

Compound TX64059: A mixture of compound **TX63762** (40.3 mg, 0.0775 mmol), TEA (0.04 mL, 0.3 mmol), DMAP (19.3 mg, 0.158 mmol), aniline (0.02 mL, 0.2 mmol) and CH₂Cl₂ (2 mL) was stirred at room temperature for 20 min. EDCI (30.5 mg, 0.159 mmol) was added, and the reaction was stirred at room temperature for 16 h. The resultant mixture was diluted with EtOAc, washed with 1 N HCl and brine, dried with Na₂SO₄, and concentrated. The residue was purified by flash chromatography (silica gel, 0% to 100% EtOAc in hexanes) to give compound **TX64059** (32.6 mg, 71%) as a white solid: ¹H NMR (400 MHz, CDCl₃) δ 8.05 (s, 1H), 7.49 (d, 2H, *J* = 8.0 Hz), 7.32 (t, 2H, *J* = 7.8 Hz), 7.16 (s, 1H), 7.11 (t, 1H, *J* = 7.4 Hz), 5.98 (s, 1H), 3.09 (d, 1H, *J* = 4.6 Hz), 2.34 (t, 2H, *J* = 8.2 Hz), 2.28 (td, 1H, *J* = 4.6, 13.1 Hz), 1.73 (m, 11H), 1.52 (s, 3H), 1.49 (s, 3H), 1.27 (m, 4H), 1.26 (s, 3H), 1.18 (s, 3H), 1.06 (m, 2H), 1.02 (s, 3H), 0.94 (s, 3H), 0.89 (s, 3H); *m/z* 595.4 (M+1).

Compound TX64075: A mixture of compound **TX63762** (49.2 mg, 0.0947 mmol), TEA (0.04 mL, 0.3 mmol), DMAP (23.5 mg, 0.192 mmol), benzylamine (0.02 mL, 0.2 mmol) and CH₂Cl₂ (2 mL) was stirred at room temperature for 15 min. EDCI (37.2 mg, 0.194 mmol) was added, and the reaction was stirred overnight at room temperature. The resultant mixture was diluted with EtOAc, washed with 1 N HCl and brine, dried with Na₂SO₄, and concentrated. The residue was purified by flash chromatography (silica gel, 0% to 100% EtOAc in hexanes) to give compound **TX64075** (14.4 mg, 25%) as a white solid: ¹H NMR (400 MHz, CDCl₃) δ 8.04 (s, 1H), 7.31 (m, 5H), 5.97 (s, 1H), 5.69 (s, 1H), 4.43 (m, 2H), 3.10 (d, 1H, *J* = 4.6 Hz), 2.24 (td, 1H, *J* = 4.1, 13.4 Hz), 2.18 (t, 2H, *J* = 8.2 Hz), 1.69 (m, 11H), 1.52 (s, 3H), 1.50 (s, 3H), 1.26 (s, 3H), 1.25 (m, 4H), 1.18 (s, 3H), 1.02 (m, 2H), 1.01 (s, 3H), 0.91 (s, 3H), 0.87 (s, 3H); *m/z* 609.4 (M+1).

Compound TX64060: A mixture of compound **TX63762** (43.9 mg, 0.0845 mmol), TEA (0.04 mL, 0.3 mmol), DMAP (18.8 mg, 0.154 mmol), dimethylamine hydrochloride (13.4 mg, 0.164 mmol) and CH₂Cl₂ (2 mL) was stirred at room temperature for 20 min.

EDCI (30.9 mg, 0.161 mmol) was added, and the reaction was stirred at room temperature for 16 h. The resultant mixture was diluted with EtOAc, washed with 1 N HCl and brine, dried with Na₂SO₄, and concentrated. The residue was purified by flash chromatography (silica gel, 0% to 100% EtOAc in hexanes) to give compound **TX64060** (35.6 mg, 77%) as a white solid: ¹H NMR (400 MHz, CDCl₃) δ 8.04 (s, 1H), 5.96 (s, 1H), 3.10 (d, 1H, *J* = 4.6 Hz), 3.03 (s, 3H), 2.94 (s, 3H), 2.34 (ddd, 1H, *J* = 5.4, 11.3, 15.7 Hz), 2.22 (m, 2H), 1.67 (m, 11H), 1.51 (s, 3H), 1.49 (s, 3H), 1.26 (s, 3H), 1.26 (m, 4H), 1.18 (s, 3H), 1.02 (m, 2H), 1.01 (s, 3H), 0.93 (s, 3H), 0.88 (s, 3H); *m/z* 547.3 (M+1).

Compound TX63950: A mixture of compound **TX63762** (521 mg, 1.00 mmol), TEA (0.42 mL, 3.0 mmol), DMAP (250 mg, 2.05 mmol), azetidine hydrochloride (188 mg, 2.01 mmol) and CH₂Cl₂ (20 mL) was stirred at room temperature for 15 min. EDCI (391 mg, 2.04 mmol) was added, and the reaction was stirred at room temperature for 25 h. The resultant mixture was diluted with EtOAc, washed with 1 N HCl and brine, dried with Na₂SO₄, and concentrated. The residue was purified by flash chromatography (silica gel, 0% to 100% EtOAc in hexanes) to give compound **TX63950** (394.6 mg, 71%) as an off-white solid: ¹H NMR (400 MHz, CDCl₃) δ 8.03 (s, 1H), 5.96 (s, 1H), 4.15 (m, 2H), 3.99 (t, 2H, *J* = 7.7 Hz), 3.10 (d, 1H, *J* = 4.6 Hz), 2.26 (m, 3H), 1.77 (m, 13H), 1.53 (s, 3H), 1.49 (s, 3H), 1.26 (s, 3H), 1.24 (m, 4H), 1.17 (s, 3H), 1.01 (m, 2H), 1.00 (s, 3H), 0.93 (s, 3H), 0.88 (s, 3H); *m/z* 559.3 (M+1).

Compound TX63949: A mixture of compound **TX63762** (520 mg, 1.00 mmol), TEA (0.42 mL, 3.0 mmol), DMAP (241 mg, 1.97 mmol), pyrrolidine (0.17 mL, 2.06 mmol) and CH₂Cl₂ (20 mL) was stirred at room temperature for 15 min. EDCI (381 mg, 1.99 mmol) was added, and the reaction was stirred at room temperature for 25 h. The resultant mixture was diluted with EtOAc, washed with 1 N HCl and brine, dried with Na₂SO₄, and concentrated. The residue was purified by flash chromatography (silica gel, 0% to 100% EtOAc in hexanes) to give **TX63949** (266.9 mg, 47%) as an off-white solid: ¹H NMR (400 MHz, CDCl₃) δ 8.04 (s, 1H), 5.96 (s, 1H), 3.44 (t, 4H, *J* = 6.9 Hz), 3.12 (d, 1H, *J* = 4.7 Hz), 2.22 (m, 3H), 1.71 (m, 15H), 1.53 (s, 3H), 1.49 (s, 3H), 1.26 (s, 3H), 1.26 (m, 4H), 1.18 (s, 3H), 1.03 (m, 2H), 1.01 (s, 3H), 0.96 (s, 3H), 0.88 (s, 3H); *m/z* 573.4 (M+1).

Compound TX63763: A mixture of compound **TX63762** (77.2 mg, 0.149 mmol), TEA (0.04 mL, 0.3 mmol), DMAP (35.6 mg, 0.291 mmol), morpholine (25 μL, 0.29 mmol) and CH₂Cl₂ (2 mL) was stirred at room temperature for 10 min. EDCI (57.8 mg, 0.301 mmol) was added, and the reaction was stirred at room temperature for 16 h. The resultant

mixture was diluted with EtOAc, washed with 1 N HCl and brine, dried with Na₂SO₄, and concentrated. The residue was purified by flash chromatography (silica gel, 0% to 100% EtOAc in hexanes) to give compound **TX63763** (66.1 mg, 82%) as a white solid: ¹H NMR (400 MHz, CDCl₃) δ 8.04 (s, 1H), 5.97 (s, 1H), 3.68 (m, 4H), 3.60 (m, 2H), 3.48 (m, 2H), 3.08 (d, 1H, *J* = 4.6 Hz), 2.33 (ddd, 1H, *J* = 5.4, 11.3, 16.4 Hz), 2.21 (m, 2H), 1.69 (m, 11H), 1.50 (s, 3H), 1.49 (s, 3H), 1.26 (s, 3H), 1.26 (m, 4H), 1.18 (s, 3H), 1.04 (m, 2H), 1.01 (s, 3H), 0.93 (s, 3H), 0.88 (s, 3H); *m/z* 589.4 (M+1).

Compound TX64045: A mixture of compound **TX63762** (39.2 mg, 0.0754 mmol), TEA (0.03 mL, 0.2 mmol), DMAP (19.5 mg, 0.160 mmol), acetic hydrazide (14.5 mg, 0.196 mmol) and CH₂Cl₂ (2 mL) was stirred at room temperature for 30 min. EDCI (31.8 mg, 0.166 mmol) was added, and the reaction was stirred at room temperature for 18 h. The resultant mixture was diluted with EtOAc, washed with 1 N HCl and brine, dried with Na₂SO₄, and concentrated. The residue was purified by flash chromatography (silica gel, 0% to 100% EtOAc in hexanes) to give compound **TX64045** (19.7 mg, 45%) as a white solid: ¹H NMR (400 MHz, CDCl₃) δ 8.04 (s, 1H), 8.00 (s, 1H), 7.96 (s, 1H), 5.98 (s, 1H), 3.07 (d, 1H, *J* = 4.6 Hz), 2.24 (m, 3H), 2.06 (s, 3H), 1.68 (s, 11H), 1.51 (s, 3H), 1.50 (s, 3H), 1.25 (m, 4H), 1.26 (s, 3H), 1.18 (s, 3H), 1.03 (m, 2H), 1.01 (s, 3H), 0.92 (s, 3H), 0.88 (s, 3H); *m/z* 576.3 (M+1).

Compound TX64049: A mixture of compound **TX63762** (40.3 mg, 0.0775 mmol), TEA (0.03 mL, 0.2 mmol), DMAP (17.9 mg, 0.147 mmol), 3,3-difluoropyrrolidine hydrochloride (23.2 mg, 0.162 mmol) and CH₂Cl₂ (2 mL) was stirred at room temperature for 15 min. EDCI (29.3 mg, 0.153 mmol) was added, and the reaction was stirred at room temperature for 18 h. The resultant mixture was diluted with EtOAc, washed with 1 N HCl and brine, dried with Na₂SO₄, and concentrated. The residue was purified by flash chromatography (silica gel, 0% to 100% EtOAc in hexanes) to give compound **TX64049** (27.9 mg, 59%) as a white solid: ¹H NMR (400 MHz, CDCl₃) δ 8.04 (s, 1H), 5.97 (s, 1H), 3.75 (m, 4H), 3.09 (t, 1H, *J* = 4.4 Hz), 2.32 (m, 5H), 1.70 (m, 11H), 1.52 (s, 3H), 1.50 (s, 3H), 1.26 (s, 3H), 1.26 (m, 4H), 1.18 (s, 3H), 1.03 (m, 2H), 1.01 (s, 3H), 0.93 (s, 3H), 0.88 (s, 3H); *m/z* 609.3 (M+1).

Compound TX64047: A mixture of compound **TX63762** (40.2 mg, 0.0774 mmol), TEA (0.03 mL, 0.2 mmol), DMAP (17.9 mg, 0.147 mmol), (*S*)-3-hydroxypyrrolidine hydrochloride (34.1 mg, 0.276 mmol) and CH₂Cl₂ (2 mL) was stirred at room temperature for 15 min. EDCI (28.5 mg, 0.149 mmol) was added, and the reaction was stirred at room

temperature for 18 h. The resultant mixture was diluted with EtOAc, washed with 1 N HCl and brine, dried with Na₂SO₄, and concentrated. The residue was purified by flash chromatography (silica gel, 0% to 100% EtOAc in hexanes) to give compound **TX64047** (20.8 mg, 46%) as a white solid: ¹H NMR (400 MHz, CDCl₃) δ [8.04 (s), 8.03 (s) (1:1, 1H)], [5.97 (s), 5.96 (s) (1:1, 1H)], 4.52 (s, 1H), 3.58 (m, 4H), [3.12 (d, *J* = 4.5 Hz), 3.09 (d, *J* = 4.5 Hz) (1:1, 1H)], 1.87 (m, 17H), [1.53 (s), 1.52 (s) (1:1, 3H)], [1.49 (s), 1.50 (s) (1:1, 3H)], 1.26 (s, 3H), 1.18 (s, 3H), 1.07 (m, 6H), 1.00 (s, 3H), [0.95 (s), 0.93 (s) (1:1, 3H)], 0.88 (s, 3H); *m/z* 589.3 (M+1).

Compound TX64048: A mixture of **TX63762** (40.1 mg, 0.0772 mmol), TEA (0.03 mL, 0.2 mmol), DMAP (19.2 mg, 0.157 mmol), 4-hydroxypiperidine (16.5 mg, 0.163 mmol) and CH₂Cl₂ (2 mL) was stirred at room temperature for 15 min. EDCI (28.4 mg, 0.148 mmol) was added, and the reaction was stirred at room temperature for 18 h. The resultant mixture was diluted with EtOAc, washed with 1 N HCl and brine, dried with Na₂SO₄, and concentrated. The residue was purified by flash chromatography (silica gel, 0% to 100% EtOAc in hexanes) to give compound **TX64048** (23.9 mg, 51%) as a white solid: ¹H NMR (400 MHz, CDCl₃) δ 8.04 (s, 1H), 5.97 (s, 1H), 4.10 (m, 1H), 3.95 (m, 1H), 3.72 (m, 2H), 3.22 (m, 2H), 3.09 (s, 1H), 2.29 (m, 5H), 1.69 (m, 13H), 1.51 (s, 3H), 1.50 (s, 3H), 1.26 (m, 4H), 1.26 (s, 3H), 1.18 (s, 3H), 1.03 (m, 2H), 1.01 (s, 3H), 0.93 (s, 3H), 0.88 (s, 3H); *m/z* 603.4 (M+1).

Compound TX64068: A mixture of compound **TX63762** (51.3 mg, 0.0987 mmol), TEA (0.05 mL, 0.4 mmol), DMAP (37.2 mg, 0.304 mmol), 2-aminopyridine (52.5 mg, 0.558 mmol) and CH₂Cl₂ (2 mL) was stirred at room temperature for 15 min. EDCI (59.2 mg, 0.309 mmol) was added, and the reaction was stirred at room temperature for 17 h. The resultant mixture was directly purified by flash chromatography (silica gel, 0% to 100% EtOAc in hexanes, each containing 0.5% TEA), then was purified by additional flash chromatography (C₁₈ silica gel, 0% to 100% MeCN in water) to give compound **TX64068** (7.0 mg, 12%) as a white solid: ¹H NMR (400 MHz, CDCl₃) δ 8.26 (d, 1H, *J* = 4.8 Hz), 8.16 (d, 1H, *J* = 8.5 Hz), 8.04 (s, 1H), 7.83 (s, 1H), 7.69 (m, 1H), 7.04 (dd, 1H, *J* = 4.8, 7.3 Hz), 5.98 (s, 1H), 3.10 (d, 1H, *J* = 4.7 Hz), 2.36 (m, 2H), 2.26 (td, 1H, *J* = 4.7, 13.4 Hz), 1.75 (m, 11H), 1.52 (s, 3H), 1.50 (s, 3H), 1.26 (m, 4H), 1.26 (s, 3H), 1.18 (s, 3H), 1.05 (m, 2H), 1.02 (s, 3H), 0.94 (s, 3H), 0.89 (s, 3H); *m/z* 596.4 (M+1).

Compound TX64044: A mixture of compound **TX63762** (39.7 mg, 0.0764 mmol), TEA (0.03 mL, 0.2 mmol), DMAP (20.3 mg, 0.166 mmol), 3-oxetanamine hydrochloride

(17.0 mg, 0.155 mmol) and CH₂Cl₂ (2 mL) was stirred at room temperature for 30 min. EDCI (30.6 mg, 0.160 mmol) was added, and the reaction was stirred at room temperature for 18 h. The resultant mixture was diluted with EtOAc, washed with 1 N HCl and brine, dried with Na₂SO₄, and concentrated. The residue was purified by flash chromatography (silica gel, 0% to 100% EtOAc in hexanes) to give compound **TX64044** (28.5 mg, 65%) as a white solid: ¹H NMR (400 MHz, CDCl₃) δ 8.04 (s, 1H), 5.97 (s, 1H), 5.94 (s, 1H), 6.74 (m, 1H), 4.92 (dt, 2H, *J* = 2.3, 7.1 Hz), 4.48 (dt, 2H, *J* = 2.9, 6.4 Hz), 3.06 (d, 1H, *J* = 4.6 Hz), 2.20 (m, 3H), 1.69 (m, 11H), 1.51 (s, 3H), 1.50 (s, 3H), 1.26 (s, 3H), 1.25 (m, 4H), 1.18 (s, 3H), 1.02 (m, 2H), 1.00 (s, 3H), 0.93 (s, 3H), 0.88 (s, 3H); *m/z* 575.3 (M+1).

Compound TX64052: A mixture of compound **TX63762** (71 mg, 0.137 mmol), TEA (0.06 mL, 0.4 mmol), DMAP (46.2 mg, 0.378 mmol), glycine methyl ester hydrochloride (33.9 mg, 0.270 mmol) and CH₂Cl₂ (3 mL) was stirred at room temperature for 15 min. EDCI (78.1 mg, 0.407 mmol) was added, and the reaction was stirred at room temperature for 16 h. The resultant mixture was diluted with EtOAc, washed with 1 N HCl and brine, dried with Na₂SO₄, and concentrated. The residue was purified by flash chromatography (silica gel, 0% to 100% EtOAc in hexanes) to give compound **TX64052** (52.0 mg, 64%) as a white solid: ¹H NMR (400 MHz, CDCl₃) δ 8.04 (s, 1H), 5.97 (s, 1H), 5.95 (s, 1H), 4.04 (dd, 2H, *J* = 5.1, 9.2 Hz), 3.77 (s, 3H), 3.08 (d, 1H, *J* = 4.7 Hz), 2.22 (m, 3H), 1.67 (m, 11H), 1.52 (s, 3H), 1.50 (s, 3H), 1.26 (s, 3H), 1.25 (m, 4H), 1.18 (s, 3H), 1.03 (m, 2H), 1.00 (s, 3H), 0.93 (s, 3H), 0.88 (s, 3H); *m/z* 591.3 (M+1).

Compound TX64054: A mixture of compound **TX64052** (20.9 mg, 0.0354 mmol), 1 N HCl (0.6 mL), and MeCN (1.2 mL) was heated to 55 °C for 22 h. The resultant mixture was diluted with EtOAc, washed with brine, dried with Na₂SO₄, and concentrated. The residue was purified by flash chromatography (silica gel, 0% to 100% EtOAc in hexanes, each with 0.5% HOAc) to give compound **TX64054** (14.6 mg, 71%) as a white solid: ¹H NMR (400 MHz, CDCl₃) δ 8.04 (s, 1H), 6.17 (s, 1H), 5.99 (s, 1H), 4.09 (dd, 2H, *J* = 5.0, 9.7 Hz), 3.07 (d, 1H, *J* = 4.6 Hz), 2.24 (m, 3H), 1.68 (m, 11H), 1.51 (s, 3H), 1.50 (s, 3H), 1.26 (s, 3H), 1.23 (m, 4H), 1.18 (s, 3H), 1.03 (m, 2H), 1.01 (s, 3H), 0.91 (s, 3H), 0.88 (s, 3H); *m/z* 577.3 (M+1).

Compound TX64124: A mixture of compound **TX63762** (47.8 mg, 0.0920 mmol), TEA (0.04 mL, 0.29 mmol), DMAP (23.5 mg, 0.192 mmol), 4-Boc-piperazine (36.3 mg, 0.195 mmol) and CH₂Cl₂ (2 mL) was stirred at room temperature for 15 min. EDCI (36.8 mg, 0.192 mmol) was added, and the reaction was stirred at room temperature for 16 h. The

resultant mixture was diluted with EtOAc, washed with 1 N HCl and brine, dried with Na₂SO₄, and concentrated. The residue was purified by flash chromatography (silica gel, 0% to 100% EtOAc in hexanes) to give compound **TX64124** (55.9 mg, 88%) as a white solid: ¹H NMR (400 MHz, CDCl₃) δ 8.04 (s, 1H), 5.97 (s, 1H), 3.57 (m, 2H), 3.42 (m, 6H), 3.08 (d, 1H, *J* = 4.6 Hz), 2.35 (m, 1H), 2.23 (m, 2H), 1.68 (m, 11H), 1.50 (s, 3H), 1.49 (s, 3H), 1.47 (s, 9H), 1.27 (m, 4H), 1.26 (s, 3H), 1.18 (s, 3H), 1.01 (s, 3H), 1.00 (m, 2H), 0.93 (s, 3H), 0.88 (s, 3H); *m/z* 588.4 (M-Boc+H+1).

Compound TX64135: HCl (4.0 M in 1,4-dioxane, 0.2 mL) was added to a room temperature solution of compound **TX64124** (49 mg, 0.071 mmol) in CH₂Cl₂ (5 mL), and the mixture was stirred at room temperature. Additional HCl solution (4.0 M in 1,4-dioxane) was added after 17 h (0.5 mL), 20 h (0.5 mL) and 2 d (2.0 mL). The resultant mixture was diluted with EtOAc, washed with 1 N NaOH and brine, dried with Na₂SO₄, and concentrated to give compound **TX64135** (14.4 mg, 35%) as an off-white solid: ¹H NMR (400 MHz, CDCl₃) δ 8.04 (s, 1H), 5.97 (s, 1H), 3.62 (m, 5H), 3.09 (d, 1H, *J* = 4.7 Hz), 2.86 (*app. td*, 4H, *J* = 5.1, 17.7 Hz), 2.34 (m, 1H), 2.22 (m, 2H), 1.68 (m, 11H), 1.51 (s, 3H), 1.49 (s, 3H), 1.26 (s, 3H), 1.24 (m, 4H), 1.18 (s, 3H), 1.03 (m, 2H), 1.01 (s, 3H), 0.93 (s, 3H), 0.88 (s, 3H); *m/z* 588.4 (M+1).

Compound TX64074: A mixture of compound **TX63762** (51.9 mg, 0.0999 mmol), NH₄Cl (18.0 mg, 0.337 mmol), EDCI (28.7 mmol, 0.150 mmol), HOBT·xH₂O (23 mg, 0.17 mmol), DIEA (0.03 mL, 0.2 mmol) and DMF (1 mL) was stirred at room temperature for 17 h. The resultant mixture was diluted with EtOAc, washed with 1 N HCl and brine, dried with Na₂SO₄, and concentrated. The residue was purified by flash chromatography (silica gel, 0% to 100% EtOAc in hexanes, each containing 0.5% TEA) to give compound **TX64074** (25.3 mg, 49%) as a white solid: ¹H NMR (400 MHz, CDCl₃) δ 8.04 (s, 1H), 5.97 (s, 1H), 5.39 (s, 1H), 5.24 (s, 1H), 3.08 (d, 1H, *J* = 4.7 Hz), 2.21 (m, 3H), 1.70 (m, 11H), 1.51 (s, 3H), 1.50 (s, 3H), 1.26 (s, 3H), 1.24 (m, 4H), 1.18 (s, 3H), 1.03 (m, 2H), 1.01 (s, 3H), 0.93 (s, 3H), 0.88 (s, 3H); *m/z* 519.3 (M+1).

Compound 13: Compound **13** was synthesized as reported in U.S. Patent No. 7,943,778, which issued on May 17, 2011, the entirety of which is incorporated herein by reference.

Compound 14: The flask containing a suspension of compound **13** (4.81 g, 10.1 mmol), Pd/C (10% w/w, 642 mg), EtOAc (100 mL), and CH₂Cl₂ (100 mL) was thoroughly purged with N₂, followed by H₂. The resultant mixture was stirred vigorously for

2 h, sparged with N₂ for ~2 h, stirred overnight at room temperature, filtered through a plug of celite (3 cm) eluting with CH₂Cl₂ (200 mL), and concentrated to give compound **14** (5.0 g) as a pale yellow foam that was used without further purification: *m/z* 480.3 (M+1).

Compound 15: A suspension of compound **14** (all above obtained, ≤ 10.1 mmol),
5 HBr (48% w/w aq., 0.49 mL, 4.4 mmol), and MeCN was heated to 35 °C for 30 min. Br₂
(0.62 mmol, 12.1 mmol) was added, and the resultant mixture was heated to 35 °C for an
additional 17 h. The solution was cooled to room temperature, 10% Na₂SO₃ (50 mL) added,
and the biphasic mixture was stirred for 15 min at room temperature. The mixture was
diluted with EtOAc. The organic fraction was separated, washed with a 1:1 mixture of 10%
10 Na₂SO₃ and sat. NaHCO₃ and brine, dried with Na₂SO₄, and concentrated to give compound
15 (5.1 g) as a yellow foam that was used without further purification: *m/z* 478.3 (M+1).

Compound 16: NaOMe (25% w/w in MeOH, 3.00 mL, 13.1 mmol) was added to a
suspension of compound **15** (all above obtained, ≤ 10.1 mmol) in MeOH (100 mL), and the
resultant mixture heated to 50 °C for 2 h. The yellow solution was cooled to room
15 temperature, diluted with MTBE, washed with 1 M HCl and brine, dried with Na₂SO₄, and
concentrated to give compound **16** (5.15 g) as a yellow foam that was used without further
purification: *m/z* 478.3 (M+1).

Compound TX63403: A solution of 1,3-dibromo-5,5-dimethylhydantoin (1.445 g,
5.05 mmol) in DMF (12 mL) was added over 5 min to a 0 °C solution of **30** (all above
20 obtained, ≤ 10.1 mmol) in DMF (40 mL). The vial containing the DBDMH solution was
washed with an addition 8 mL of DMF, and that solution was added to the reaction. After 1 h
at 0 °C, pyridine (2.45 mL, 30.3 mmol) was added, and the reaction was heated to 55 °C for 4
h. The resultant solution was cooled to room temperature, diluted with EtOAc, washed with
10% Na₂SO₃, water, 1 N HCl, and brine, dried with Na₂SO₄, and concentrated. The residue
25 was purified by flash chromatography (silica gel, 0% to 42% EtOAc in hexanes), and the
resultant product was triturated with EtOH (50 mL) at 50 °C for 30 min to give compound
TX63403 (3.01 g, 63% from **13**) as a white solid: ¹H NMR (500 MHz, CDCl₃) δ 8.05 (s, 1H),
5.97 (s, 1H), 3.02 (d, 1H, *J* = 4.7 Hz), 2.23 (td, 1H, *J* = 4.3, 13.5 Hz), 1.78 (m, 6H), 1.54 (m,
3H), 1.50 (s, 3H), 1.46 (s, 3H), 1.40 (m, 1H), 1.26 (s, 3H), 1.22 (m, 5H), 1.18 (s, 3H), 1.03
30 (m, 2H), 1.00 (s, 3H), 0.92 (s, 3H), 0.87 (s, 3H), 0.83 (t, 3H, *J* = 7.4 Hz); *m/z* 476.3 (M+1).

Compound TX63868: Compound **TX63355** (500 mg, 1.05 mmol) and
1,1'-carbonyldiimidazole (221 mg, 1.36 mmol) were dissolved in MeCN (10 mL). The
reaction was heated at reflux for 5 h and was then cooled to room temperature. The

precipitate was collected by filtration and was then washed with MeCN and dried under vacuum to give compound **TX63868** (446 mg, 75%) as a white solid: ^1H NMR (400 MHz, CDCl_3) δ 8.15 (s, 1H), 8.03 (s, 1H), 7.42 (s, 1H), 7.10 (s, 1H), 6.00 (s, 1H), 4.43 (d, 1H, $J = 10.8$ Hz), 4.36 (d, 1H, $J = 10.8$ Hz), 3.00 (d, 1H, $J = 4.7$ Hz), 2.44 (m, 1H), 2.00 (ddd, 1H, $J = 4.3, 13.9, 13.9$ Hz), 1.72-1.90 (m, 7H), 1.58 (m, 1H), 1.52 (s, 3H), 1.51 (s, 3H), 1.26 (s, 3H), 1.18 (s, 3H), 1.15-1.44 (m, 6H), 1.05 (s, 3H), 0.97 (s, 3H), 0.91 (s, 3H); m/z 572.3 (M+1).

Compound TX63926: A mixture of compound **TX63355** (200 mg, 0.42 mmol), 4-morpholinecarbonyl chloride (0.15 mL, 1.28 mmol), DMAP (5 mg, 0.041 mmol), and pyridine (1 mL) was stirred at rt for 30 min, then at 90 °C for 18 h. The reaction was cooled to rt, and Ac_2O (0.2 mL) was added. After the reaction was stirred for 30 min, aq. NaHCO_3 solution was added. The reaction was stirred for another 30 min and was then extracted with EtOAc. The combined organic extracts were washed with 1 N HCl and then NaHCO_3 solution, dried with Na_2SO_4 , and concentrated. The residue was purified by column chromatography (silica gel, 0% to 45% EtOAc in hexanes) to give compound **TX63926** (122 mg, 49%) as a white foam: ^1H NMR δ 8.06 (s, 1H), 6.00 (s, 1H), 4.20 (d, 1H, $J = 11.0$ Hz), 4.04 (d, 1H, $J = 11.0$ Hz), 3.69 (bs, 4H), 3.51 (bs, 4H), 3.07 (d, 1H, $J = 4.6$ Hz), 2.42 (m, 1H), 1.72-1.98 (m, 7H), 1.61 (m, 1H), 1.53 (s, 3H), 1.52 (s, 3H), 1.49 (m, 1H), 1.28 (s, 3H), 1.20 (s, 3H), 1.08-1.36 (m, 6H), 1.04 (s, 3H), 0.96 (s, 3H), 0.91 (s, 3H); m/z 591.4 (M+1).

Compound TX63927: A mixture of compound **TX63355** (200 mg, 0.42 mmol), 1-pyrrolidinecarbonyl chloride (0.14 mL, 1.27 mmol), DMAP (5 mg, 0.041 mmol) and pyridine (1 mL) was stirred at rt for 30 min, and then at 90 °C for 18 h. The reaction was cooled to rt, and Ac_2O (0.2 mL) was added. After the reaction was stirred for 30 min, aq. NaHCO_3 solution was added. The reaction was stirred for another 30 min and was then extracted with EtOAc. The combined organic extracts were washed with 1 N HCl and NaHCO_3 solution, dried with Na_2SO_4 , and concentrated. The residue was purified by column chromatography (silica gel, 0% to 40% EtOAc in hexanes) to give compound **TX63927** (85 mg, 35%) as a white foam: ^1H NMR δ 8.07 (s, 1H), 5.99 (s, 1H), 4.20 (d, 1H, $J = 10.9$ Hz), 3.94 (d, 1H, $J = 10.9$ Hz), 3.40 (m, 4H), 3.09 (d, 1H, $J = 4.6$ Hz), 2.48 (m, 1H), 1.72-2.00 (m, 11H), 1.60 (m, 1H), 1.53 (s, 3H), 1.52 (s, 3H), 1.49 (m, 1H), 1.28 (s, 3H), 1.20 (s, 3H), 1.08-1.36 (m, 6H), 1.04 (s, 3H), 0.97 (s, 3H), 0.91 (s, 3H); m/z 575.4 (M+1).

Compound TX63930: A mixture of compound **TX63355** (200 mg, 0.42 mmol), ethyl isocyanate (0.33 mL, 4.17 mmol), and toluene (1 mL) was stirred at rt for 30 min, and then at 90 °C for 16 h. The reaction was cooled to rt and was purified directly by column

chromatography (silica gel, 0% to 50% EtOAc in hexanes) to give compound TX63930 (196 mg, 85% yield) as a white foam: ^1H NMR δ 8.07 (s, 1H), 6.00 (s, 1H), 4.70 (m, 1H), 4.12 (d, 1H, $J = 11.0$ Hz), 4.00 (d, 1H, $J = 11.0$ Hz), 3.24 (m, 2H), 3.08 (d, 1H, $J = 4.4$ Hz), 2.42 (m, 1H), 1.53 (s, 3H), 1.52 (s, 3H), 1.28 (s, 3H), 1.20 (s, 3H), 1.17 (t, 3H, $J = 7.3$ Hz), 1.08-1.97 (m, 15H), 1.04 (s, 3H), 0.97 (s, 3H), 0.90 (s, 3H); m/z 549.3 ($M+1$).

Compound 17: LiAlH_4 (2.0 M in THF, 100 mL, 200 mmol) was added to a 0 °C solution of oleanolic acid (25.1 g, 55.0 mmol) in THF (1.25 L). The mixture was heated to reflux for 3 h, cooled to room temperature overnight, cooled to 0 °C, quenched by the successive addition of water (10.6 mL), 4 M NaOH (10.6 mL) and water (10.6 mL), warmed to room temperature over 15 min, filtered through celite, eluted with MTBE, and concentrated to give compound 17 as a white solid that was used without further purification: m/z 443.4 ($M+1$).

Compound 18: A solution of NaOCl (6.0%, 80 mL, 65 mmol) and water (180 mL) was added to a 0 °C biphasic solution of compound 17 (all above obtained, ≤ 55.0 mmol), NaHCO_3 (4.65 g, 55.4 mmol), NaBr (5.68 g, 55.2 mmol), TEMPO (4.30 g, 27.5 mmol), water (360 mL) and CH_2Cl_2 (1 L) over 1 h. The mixture was warmed to room temperature over 16 h, quenched by the addition of 10% Na_2SO_3 and stirred for 15 min. The organic fraction was separated, and the aqueous fraction was extracted with CH_2Cl_2 . The combined organic fraction was washed with brine, dried with Na_2SO_4 , and concentrated. The residue was purified by flash chromatography (silica gel, 0% to 15% EtOAc in hexanes, then 10% EtOAc in CH_2Cl_2) to give compound 18 (19.22 g, 79% from oleanolic acid) as an off-white solid: m/z 441.4 ($M+1$).

Compound 19: KO^tBu (6.36 g, 56.8 mmol) was added to a room temperature suspension of (methoxymethyl)triphenylphosphonium chloride (23.36 g, 68.14 mmol) in THF (115 mL) and stirred at room temperature for 45 min. A solution of 19 (5.00 g, 11.4 mmol) in THF (85 mL) was added over 10 min to the reaction mixture, and the transfer was completed with THF (30 mL). The reaction was stirred at room temperature for 21 h, then quenched by the addition of H_2SO_4 (30%, 23 mL), stirred 2 h, diluted with EtOAc and water, and made basic with 4 N NaOH. The organic fraction was separated, washed with brine, dried with Na_2SO_4 , and concentrated. The residue was purified by flash chromatography (silica gel, 0% to 30% EtOAc in hexanes) to give compound 19 (4.93 g, 96%) as a pale yellow solid: m/z 455.4 ($M+1$).

Compound 20: NaBH_4 (856 mmol, 22.6 mmol) was added to a 0 °C solution of compound 19 (4.93 g, 10.8 mmol) in MeOH/THF (2:1 mixture, 300 mL), and the reaction

was allowed to warm to room temperature. After 2 h at room temperature, the mixture was concentrated to reduced volume, diluted with EtOAc, washed with 1 N HCl and brine, dried with Na₂SO₄, and concentrated to give compound **20** (6 g, quantitative) as a white solid: *m/z* 457.4 (M+1).

5 **Compound 21:** A solution of **20** (all above obtained, ≤ 10.8 mmol), Ac₂O (8.2 mL, 87 mmol), pyridine (10.5 mL, 130 mmol), and DMAP (133 mg, 1.09 mmol) in CH₂Cl₂ (225 mL) was stirred at room temperature. Additional Ac₂O (4.1 mL, 43 mmol), pyridine (5.25 mL, 64.9 mmol), and DMAP (133 mg, 1.09 mmol) were added after 7 h and again after an additional 16 h. The reaction was stirred an additional 3 d, then diluted with CH₂Cl₂, washed
10 with 1 N HCl, saturated NaHCO₃ and brine, dried with Na₂SO₄, and concentrated. The residue was purified by flash chromatography (silica gel, 0% to 30% EtOAc in hexanes) to give compound **21** (4.40 g, 75% from **19**) as a white foam solid.

Compound 22: AcOOH (39% in AcOH, 2.1 mL, 12.4 mmol) was added to a 50 °C suspension of **21** (4.40 g, 8.14 mmol) and Na₂CO₃ (1.13 g, 10.7 mmol) in AcOH (81 mL).
15 Additional AcOOH (0.84 mL, 5.0 mmol) was added after 17 h and again (0.21 mL, 1.2 mmol) after an additional 8 h. The reaction was stirred at 50 °C for an additional 18 h, quenched by the addition of excess Na₂SO₃, stirred 15 min, diluted with toluene, and concentrated to dryness. The residue was dissolved in CH₂Cl₂, washed with water, saturated NaHCO₃ and brine, dried with Na₂SO₄, and concentrated to give compound **22** (4.36 g, 96 %)
20 as a white solid: *m/z* 557.4 (M+1).

Compound 23: Br₂ (0.60 mL, 12 mmol) was added to a 35 °C suspension of compound **22** (5.41 g, 9.72 mmol) and HCl (4.0 M in 1,4-dioxane, 0.97 mL, 3.9 mmol) in MeCN (96 mL). The mixture was stirred overnight between room temperature and 35 °C. The mixture was heated to 35 °C, and additional Br₂ (0.15 mL, 2.9 mmol) was added and
25 again added (0.30 mL, 5.8 mmol) after an additional 1 h. The reaction was stirred at 35 °C for an additional 1 h, then quenched by the addition of 4% Na₂SO₃ (100 mL) and stirred at room temperature for 30 min. The organic fraction was washed with saturated NaHCO₃ and brine, dried with Na₂SO₄, and concentrated to give compound **23** as a yellow solid: *m/z* 555.4 (M+1).

30 **Compound 24:** A solution of compound **23** (all above obtained, ≤ 9.72 mmol) and concentrated H₂SO₄ (0.1 mL) in MeOH/THF (1:1 mixture, 200 mL) was heated to 35 °C for 1 h. Additional H₂SO₄ (0.9 mL) was added, and the reaction was then brought to reflux for 19 h. The mixture was concentrated to reduced volume, then diluted with EtOAc, washed with 1 N NaOH and brine, dried with Na₂SO₄, and concentrated. The residue was purified by flash

chromatography (silica gel, 0% to 65% EtOAc in CH₂Cl₂) to give compound **24** (3.41 g, 74% from **22**) as a pale-yellow solid: *m/z* 471.4 (M+1).

Compound 25: A solution of NaOCl (6%, 6.5 mL, 5.2 mmol) was added to a room temperature solution of compound **24** (1.70 g, 3.61 mmol) in AcOH (27.5 mL), and the
5 reaction mixture was stirred at room temperature for 1.5 h. The reaction was diluted with EtOAc, washed with 10% Na₂SO₃ and brine, dried with Na₂SO₄, and concentrated. The residue was purified by flash chromatography (silica gel, 0% to 55% EtOAc in CH₂Cl₂) to give compound **25** (1.36 g, 80%) as a white solid: *m/z* 469.3 (M+1).

Compound 26: NaOMe (25% in MeOH, 6.5 mL) was added to a 0 °C solution of
10 compound **25** (1.36 g, 2.90 mmol) in ethyl formate (16.5 mL). The mixture was stirred at 0 °C for 15 min, then warmed to room temperature. After 7 h the mixture was diluted with EtOAc, washed with 1 N HCl and brine, dried with Na₂SO₄, and concentrated to give compound **26** (plus mixture of formate esters) as a yellow foam: *m/z* 497.3 (M+1).

Compound 27: A mixture of compound **26** (all above obtained, ≤ 2.90 mmol) and
15 NH₂OH·HCl in EtOH/water was heated to 55 °C for 17 h. The resultant mixture was diluted with EtOAc, washed with 1 N HCl and brine, dried with Na₂SO₄, and concentrated to give compound **27** as a yellow foam: *m/z* 494.4 (M+1).

Compound 28: A solution of **27** (all above obtained, ≤ 2.90 mmol) and NaOMe (25% in MeOH, 1.7 mL) in MeOH (39 mL) was heated to 55 °C for 6 h. The mixture was
20 cooled to room temperature overnight, acidified with HCl (4 M in 1,4-dioxane, 10 mL), and heated to 55 °C for 7 h. The resultant mixture was diluted with EtOAc, washed with 1 N HCl and brine, dried with Na₂SO₄, and concentrated. The residue was purified by flash chromatography (silica gel, 0% to 100% EtOAc in hexanes) to give compound **28** (1.01 g, 71% from **25**) as a pale-yellow foam solid: *m/z* 494.3 (M+1).

Compound TX63608: A solution of 1,3-dibromo-5,5-dimethylhydantoin (309 mg, 1.08 mmol) in DMF (3 mL) was added to a 0 °C solution of compound **28** (1.01 g, 2.05 mmol) in DMF (15 mL), with additional DMF (2 mL) used to complete the transfer. The mixture was stirred at 0 °C for 3.5 h, then pyridine (0.66 mL, 8.2 mmol) was added, and the
25 reaction was heated to 55 °C for 18 h. The resultant solution was diluted with EtOAc, washed with 1 N HCl, 5% Na₂SO₃, and brine, dried with Na₂SO₄, and concentrated. The residue was purified by column chromatography (silica gel, 0% to 100% EtOAc in hexanes) to give compound **TX63608** (805 mg, 80 %) as an off-white solid: ¹H NMR (400 MHz, CDCl₃) δ 8.04 (s, 1H), 5.98 (s, 1H), 3.78 (m, 2H), 3.11 (d, 1H, *J* = 4.7 Hz), 2.25 (td, 1H, *J* =

4.0, 13.6 Hz), 1.65 (m, 12H), 1.50 (s, 3H), 1.50 (s, 3H), 1.26 (s, 3H), 1.25 (m, 4H), 1.18 (s, 3H), 1.06 (m, 2H), 1.01 (s, 3H), 0.93 (s, 3H), 0.87 (s, 3H); m/z 492.3 (M+1).

Compound TX63609: A solution of compound **TX63608** (50.5 mg, 0.103 mmol), MeOTf (57 μ L, 0.50 mmol) and 2,6-di-*tert*-butyl-4-methylpyridine (128 mg, 0.623 mmol) in CH_2Cl_2 (2 mL) was stirred at room temperature for 19 h. The resultant mixture was diluted with EtOAc, washed with 1 N HCl and brine, dried with Na_2SO_4 , and concentrated. The residue was purified by column chromatography (silica gel, 0% to 100 % EtOAc in hexanes) to give compound **TX63609** (39.5 mg, 76 %) as a white solid: ^1H NMR (400 MHz, CDCl_3) δ 8.04 (s, 1H), 5.97 (s, 1H), 3.45 (m, 2H), 3.32 (s, 3H), 3.09 (d, 1H, $J = 4.7$ Hz), 2.25 (td, 1H, $J = 4.1, 13.4$ Hz), 1.66 (m, 11H), 1.50 (s, 3H), 1.48 (s, 3H), 1.26 (s, 3H), 1.25 (m, 4H), 1.18 (s, 3H), 1.05 (m, 2H), 1.01 (s, 3H), 0.94 (s, 3H), 0.87 (s, 3H); m/z 506.3 (M+1).

Compound TX63610: A solution of compound **TX63608** (49.6 mg, 0.101 mmol), Ac_2O (48 μ L, 0.51 mmol), pyridine (81 μ L, 1.0 mmol) and DMAP (3.4 mg, 0.028 mmol) in CH_2Cl_2 (2 mL) was stirred at room temperature for 20 h. The resultant mixture was diluted with EtOAc, washed with 1 N HCl, saturated NaHCO_3 , and brine, dried with Na_2SO_4 , and concentrated. The residue was purified by column chromatography (silica gel, 0% to 100% EtOAc in hexanes) to give compound **TX63610** (41.1 mg, 76%) as a white solid: ^1H NMR (400 MHz, CDCl_3) δ 8.04 (s, 1H), 5.98 (s, 1H), 4.16 (m, 2H), 3.08 (d, 1H, $J = 4.7$ Hz), 2.25 (td, 1H, $J = 4.0, 13.5$ Hz), 2.03 (s, 3H), 1.66 (m, 11H), 1.50 (s, 3H), 1.49 (s, 3H), 1.26 (s, 3H), 1.25 (m, 4H), 1.18 (s, 3H), 1.07 (m, 2H), 1.01 (s, 3H), 0.93 (s, 3H), 0.87 (s, 3H); m/z 534.3 (M+1).

Compound TX63981: A solution of compound **TX63608** (41.4 mg, 0.0842 mmol) and EtNCO (64 μ L, 0.81 mmol) in toluene (0.5 mL) was stirred at room temperature for 1 h, then heated to 70 $^\circ\text{C}$ for >4 h. The reaction mixture was cooled to room temperature and was purified directly by column chromatography (silica gel, 0% to 100 % EtOAc in hexanes) to give compound **TX63981** (34.5 mg, 73%) as a white solid: ^1H NMR (400 MHz, CDCl_3) δ 8.04 (s, 1H), 5.97 (s, 1H), 4.58 (s, 1H), 4.23 (m, 1H), 4.12 (m, 1H), 3.19 (m, 2H), 3.09 (d, 1H, $J = 4.6$ Hz), 2.30 (td, 1H, $J = 4.1, 13.2$ Hz), 1.67 (m, 11H), 1.50 (s, 3H), 1.49 (s, 3H), 1.26 (s, 3H), 1.19 (m, 6 H), 1.18 (s, 3H), 1.12 (t, 3H, $J = 7.2$ Hz), 1.01 (s, 3H), 0.94 (s, 3H), 0.88 (s, 3H); m/z 563.4 (M+1).

Compound 29: DIBAL-H (1.0 M in THF, 5 mL, 5.0 mmol) was added to a 0 $^\circ\text{C}$ solution of **8a**, **8b** (**8a:8b** = 2:3, 0.50 g, 0.92 mmol) in THF (10 mL). The reaction mixture was stirred at 0 $^\circ\text{C}$ for 30 min, then warmed to room temperature for 2.5 h. The mixture was

cooled to 0 °C, quenched with saturated NaK tartrate (10 mL), diluted with MTBE (25 mL), warmed to room temperature over 1 h, diluted with additional saturated NaK tartrate (40 mL), then and extracted with MTBE. The combined organic fractions were washed with brine, dried with Na₂SO₄, filtered through a short plug of celite, eluted with MTBE, and concentrated to give compound **29** (491 mg, mixture of C12-epimers, quantitative) as a white solid: *m/z* 492.3 (M+1).

Compound 30: NBS (244 mg, 1.37 mmol) was added to a room temperature solution of compound **29** (all above obtained, ≤ 0.92 mmol) in DME/water (9:1 mixture, 10 mL). The reaction was stirred at room temperature for 2 h, quenched by the addition of 5% Na₂SO₃, stirred 15 min at room temperature, and then extracted with EtOAc. The organic fraction was washed with brine, dried with Na₂SO₄, and concentrated. The residue was purified by flash chromatography (silica gel, 0% to 100% EtOAc in hexanes) to give compound **30** (491 mg, quantitative) as a white solid: *m/z* 508.3 (M+1).

Compound 31: A solution of compound **30** (all above obtained, ≤ 0.92 mmol) and NaOMe (25% in MeOH, 1.3 mL) in MeOH was stirred at 55 °C for 16 h. The resultant mixture was diluted with 1 N HCl and extracted with EtOAc. The combined organic fractions were washed with brine, dried with Na₂SO₄, and concentrated. The residue was purified by flash chromatography (silica gel, 0% to 80% EtOAc in hexanes) to give compound **31** (151 mg, 32%) as a white solid: *m/z* 508.3 (M+1).

Compound TX63744: 1,3-dibromo-5,5-dimethylhydantoin (45 mg, 0.16 mmol) was added to a 0 °C solution of compound **31** (151 mg, 0.278 mmol) in DMF (10 mL). The mixture was stirred at 0 °C for 2.5 h. Pyridine (0.10 mL, 1.2 mmol) was then added, and the reaction heated to 55 °C overnight. The resultant solution was diluted with EtOAc, washed with 1 N HCl, 10% Na₂SO₃, and brine, dried with Na₂SO₄, and concentrated. The residue was purified by column chromatography (silica gel, 0% to 80% EtOAc in hexanes) to give compound **TX63744** (82 mg, 58%) as a white solid: ¹H NMR (400 MHz, CDCl₃) δ 8.04 (s, 1H), 5.97 (s, 1H), 3.66 (m, 2H), 3.05 (d, 1H, *J* = 4.7 Hz), 2.25 (td, 1H, *J* = 4.1, 13.6 Hz), 1.66 (m, 14H), 1.49 (s, 3H), 1.47 (s, 3H), 1.26 (s, 3H), 1.23 (m, 4H), 1.18 (s, 3H), 1.04 (m, 2H), 1.01 (s, 3H), 0.93 (s, 3H), 0.87 (s, 3H); *m/z* 506.3 (M+1).

Compound TX63983: A solution of compound **TX63744** (24.1 mg, 0.0477 mmol) and EtNCO (39 μL, 0.49 mmol) in toluene (0.5 mL) was heated to 70 °C for 20 h, then purified directly by column chromatography (silica gel, 0% to 100% EtOAc in hexanes) to give compound **TX63983** (20.7 mg, 75%) as a white solid: ¹H NMR (400 MHz, CDCl₃) δ

8.04 (s, 1H), 5.98 (s, 1H), 4.55 (s, 1H), 4.04 (m, 2H), 3.21 (m, 2H), 3.02 (d, 1H, $J = 4.6$ Hz), 2.24 (td, 1H, $J = 4.0, 12.8$ Hz), 1.66 (m, 13H), 1.50 (s, 3H), 1.46 (s, 3H), 1.26 (s, 3H), 1.25 (m, 4H), 1.18 (s, 3H), 1.14 (t, 3H, $J = 7.2$ Hz), 1.04 (m, 2H), 1.01 (s, 3H), 0.93 (s, 3H), 0.88 (s, 3H); m/z 577.4 (M+1).

5

All of the compounds, compositions and methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the disclosure may have only been described in terms of certain embodiments, it will be apparent to those of skill in the art that variations may be applied to the compounds, compositions and methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.

10

15

REFERENCES

The following references to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference.

5

U.S. Patent No. 7,915,402

U.S. Patent No. 7,943,778

U.S. Patent No. 8,071,632

U.S. Patent No. 8,124,799

10 U.S. Patent No. 8,129,429

U.S. Patent No. 8,338,618

Abraham and Kappas, *Free Radical Biol. Med.*, 39:1-25, 2005.

Ahmad *et al.*, *Cancer Res.*, 68:2920-2926, 2008.

15 Ahmad *et al.*, *J. Biol. Chem.*, 281:35764-9, 2006.

Araujo *et al.*, *J. Immunol.*, 171(3):1572-1580, 2003.

Bach, *Hum. Immunol.*, 67(6):430-432, 2006.

Chauhan and Chauhan, *Pathophysiology*, 13(3):171-181 2006.

Dickerson *et al.*, *Prog Neuropsychopharmacol Biol. Psychiatry*, March 6, 2007.

20 Dinkova-Kostova *et al.*, *Proc. Natl. Acad. Sci. USA*, 102(12):4584-4589, 2005.

Dudhgaonkar *et al.*, *Eur. J. Pain*, 10(7):573-9, 2006.

Forstermann, *Biol. Chem.*, 387:1521, 2006.

Handbook of Pharmaceutical Salts: Properties, and Use, Stahl and Wermuth Eds.), Verlag Helvetica Chimica Acta, 2002.

25 Hanson *et al.*, *BMC Medical Genetics*, 6(7), 2005.

Honda *et al.* *Bioorg. Med. Chem. Lett.*, 12:1027--1030, 2002.

Honda *et al.*, *J. Med. Chem.*, 43:4233--4246, 2000a.

Honda, *et al.*, *J. Med. Chem.*, 43:1866--1877, 2000b.

Honda *et al.*, *Bioorg. Med. Chem. Lett.*, 7:1623-1628, 1997.

30 Honda *et al.*, *Bioorg. Med. Chem. Lett.*, 9(24):3429-3434, 1999.

Honda *et al.*, *Bioorg. Med. Chem. Lett.*, 8(19):2711-2714, 1998.

Honda *et al.*, *Bioorg. Med. Chem. Lett.*, 16(24):6306-6309, 2006.

Hong *et al.*, *Clin Cancer Res*, 18(12):3396-406, 2012.

- Ishikawa *et al.*, *Circulation*, 104(15):1831-1836, 2001.
- Kawakami *et al.*, *Brain Dev.*, 28(4):243-246, 2006.
- Kendall-Tackett, *Trauma Violence Abuse*, 8(2):117-126, 2007.
- Kruger *et al.*, *J. Pharmacol. Exp. Ther.*, 319(3):1144-1152, 2006.
- 5 Lee *et al.*, *Glia*, 55(7):712-22, 2007.
- Lencz *et al.*, *Mol. Psychiatry*, 12(6):572-80, 2007.
- Liby *et al.*, *Cancer Res.*, 65(11):4789-4798, 2005.
- Liby *et al.*, *Nat. Rev. Cancer*, 7(5):357-356, 2007a.
- Liby *et al.*, *Mol. Cancer Ther.*, 6(7):2113-9, 2007b.
- 10 Liby *et al.*, 2007b
- Liu *et al.*, *FASEB J.*, 20(2):207-216, 2006.
- Lu *et al.*, *J. Clin. Invest.*, 121(10):4015-29, 2011.
- March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure*, 2007.
- Melver *et al.*, *Pain*, 120(1-2):161-9, 2005.
- 15 Morris *et al.*, *J. Mol. Med.*, 80(2):96-104, 2002.
- Morse and Choi, *Am. J. Respir. Crit. Care Med.*, 172(6):660-670, 2005.
- Morse and Choi, *Am. J. Respir. Crit. Care Med.*, 27(1):8-16, 2002.
- Pall, *Med. Hypoth.*, 69:821-825, 2007.
- Pergola *et al.*, *N Engl J Med*, 365:327-336, 2011.
- 20 Place *et al.*, *Clin. Cancer Res.*, 9(7):2798-806, 2003.
- Rajakariar *et al.*, *Proc. Natl. Acad. Sci. USA*, 104(52):20979-84, 2007.
- Ross *et al.*, *Am. J. Clin. Pathol.*, 120(Suppl):S53-71, 2003.
- Ross *et al.*, *Expert Rev. Mol. Diagn.*, 3(5):573-585, 2003.
- Ruster *et al.*, *Scand. J. Rheumatol.*, 34(6):460-3, 2005.
- 25 Sacerdoti *et al.*, *Curr Neurovasc Res.* 2(2):103-111, 2005.
- Salvemini *et al.*, *J. Clin. Invest.*, 93(5):1940-1947, 1994.
- Sarchielli *et al.*, *Cephalalgia*, 26(9):1071-1079, 2006.
- Satoh *et al.*, *Proc. Natl. Acad. Sci. USA*, 103(3):768-773, 2006.
- Schulz *et al.*, *Antioxid. Redox. Sig.*, 10:115, 2008.
- 30 Strejan *et al.*, *J. Neuroimmunol.*, 7:27, 1984.
- Suh *et al.*, *Cancer Res.*, 58:717-723, 1998.
- Suh *et al.*, *Cancer Res.*, 59(2):336-341, 1999.
- Szabo *et al.*, *Nature Rev. Drug Disc.*, 6:662-680, 2007.
- Takahashi *et al.*, *Cancer Res.*, 57:1233-1237, 1997.


Tamir and Tannebaum, *Biochim. Biophys. Acta*, 1288:F31-F36, 1996.

Xie *et al.*, *J. Biol. Chem.*, 270(12):6894-6900, 1995.

Zhou *et al.*, *Am. J. Pathol.*, 166(1):27-37, 2005.

CLAIMS


1. A compound of the formula:



wherein:

- 5 Y is a covalent bond, $-\text{CH}_2-$, $-\text{C}(\text{O})-$, $-\text{O}-$, or $-\text{NH}-$;
 R_1 and R_2 are each independently $-\text{H}$, $-\text{OH}$, methyl, or as defined below; and
 R_3 is:
 hydrogen, hydroxy, halo, amino, $-\text{NHOH}$, or mercapto;
 $\text{alkyl}_{(\text{C}\leq 8)}$, $\text{alkenyl}_{(\text{C}\leq 8)}$, $\text{alkynyl}_{(\text{C}\leq 8)}$, $\text{aryl}_{(\text{C}\leq 8)}$, $\text{aralkyl}_{(\text{C}\leq 8)}$, $\text{heteroaryl}_{(\text{C}\leq 8)}$,
 10 $\text{heterocycloalkyl}_{(\text{C}\leq 8)}$, $\text{acyl}_{(\text{C}\leq 8)}$, $\text{alkoxy}_{(\text{C}\leq 8)}$, $\text{alkenyloxy}_{(\text{C}\leq 8)}$,
 $\text{aryloxy}_{(\text{C}\leq 8)}$, $\text{aralkoxy}_{(\text{C}\leq 8)}$, $\text{heteroaryloxy}_{(\text{C}\leq 8)}$, $\text{acyloxy}_{(\text{C}\leq 8)}$,
 $\text{heterocycloalkoxy}_{(\text{C}\leq 8)}$, $\text{alkylamino}_{(\text{C}\leq 8)}$, $\text{dialkylamino}_{(\text{C}\leq 8)}$,
 $\text{alkenylamino}_{(\text{C}\leq 8)}$, $\text{alkoxyamino}_{(\text{C}\leq 8)}$, $\text{arylamino}_{(\text{C}\leq 8)}$,
 $\text{aralkylamino}_{(\text{C}\leq 8)}$, $\text{heteroarylamino}_{(\text{C}\leq 8)}$, heterocyclo-
 15 $\text{alkylamino}_{(\text{C}\leq 8)}$, $\text{alkylsulfonylamino}_{(\text{C}\leq 8)}$, $\text{amido}_{(\text{C}\leq 8)}$,
 $-\text{NH}-\text{amido}_{(\text{C}\leq 8)}$, or a substituted version of any of these
 groups;
 R_3 and R_1 , taken together, are $-\text{O}-$, $-\text{NR}_a-$ or a covalent bond between
 Y and carbon atom 13, wherein R_a is hydrogen or $\text{alkyl}_{(\text{C}\leq 4)}$; or
 20 R_3 and R_2 , taken together, are $-\text{O}-$, $-\text{NR}_a-$ or a covalent bond between
 Y and carbon atom 14, wherein R_a is hydrogen or $\text{alkyl}_{(\text{C}\leq 4)}$;
 or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 further defined as:



wherein:

Y is $-\text{CH}_2-$, $-\text{C}(\text{O})-$, $-\text{O}-$, or $-\text{NH}-$;

5 R_1 and R_2 are each independently $-\text{H}$, $-\text{OH}$, methyl, or as defined below; and R_3 is:

hydrogen, hydroxy, halo, amino, $-\text{NHOH}$, or mercapto;

alkyl_(C≤8), alkenyl_(C≤8), alkynyl_(C≤8), aryl_(C≤8), aralkyl_(C≤8), heteroaryl_(C≤8),

heterocycloalkyl_(C≤8), acyl_(C≤8), alkoxy_(C≤8), alkenyloxy_(C≤8),

10 aryloxy_(C≤8), aralkoxy_(C≤8), heteroaryloxy_(C≤8), acyloxy_(C≤8),

heterocycloalkoxy_(C≤8), alkylamino_(C≤8), dialkylamino_(C≤8),

alkenylamino_(C≤8), alkoxyamino_(C≤8), arylamino_(C≤8),

aralkylamino_(C≤8), heteroarylamino_(C≤8), heterocyclo-

alkylamino_(C≤8), alkylsulfonylamino_(C≤8), amido_(C≤8),

15 $-\text{NH}-\text{amido}_{(C≤8)}$, or a substituted version of any of these groups;


R_3 and R_1 , taken together, are $-\text{O}-$, $-\text{NR}_a-$ or a covalent bond between Y and carbon atom 13, wherein R_a is hydrogen or alkyl_(C≤4); or

R_3 and R_2 , taken together, are $-\text{O}-$, $-\text{NR}_a-$ or a covalent bond between

20 Y and carbon atom 14, wherein R_a is hydrogen or alkyl_(C≤4);

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1, further defined as:



wherein:

Y is a covalent bond, $-\text{CH}_2-$, $-\text{C}(\text{O})-$, $-\text{O}-$, or $-\text{NH}-$; and

R₃ is:

hydrogen, hydroxy, halo, amino, $-\text{NHOH}$, or mercapto; or

alkyl_(C≤8), alkenyl_(C≤8), alkynyl_(C≤8), aryl_(C≤8), aralkyl_(C≤8), heteroaryl_(C≤8),

heterocycloalkyl_(C≤8), acyl_(C≤8), alkoxy_(C≤8), alkenyloxy_(C≤8),

aryloxy_(C≤8), aralkoxy_(C≤8), heteroaryloxy_(C≤8), acyloxy_(C≤8),

heterocycloalkoxy_(C≤8), alkylamino_(C≤8), dialkylamino_(C≤8),

alkenylamino_(C≤8), alkoxyamino_(C≤8), arylamino_(C≤8),

aralkylamino_(C≤8), heteroarylamino_(C≤8), heterocyclo-


alkylamino_(C≤8), alkylsulfonylamino_(C≤8), amido_(C≤8),

$-\text{NH}-$ amido_(C≤8), or a substituted version of any of these

groups;

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 3, further defined as:



wherein:

Y is $-\text{CH}_2-$, $-\text{C}(\text{O})-$, $-\text{O}-$, or $-\text{NH}-$; and

R₃ is:

hydrogen, hydroxy, halo, amino, $-\text{NHOH}$, or mercapto; or
 alkyl_(C≤8), alkenyl_(C≤8), alkynyl_(C≤8), aryl_(C≤8), aralkyl_(C≤8), heteroaryl_(C≤8),
 heterocycloalkyl_(C≤8), acyl_(C≤8), alkoxy_(C≤8), alkenyloxy_(C≤8),
 aryloxy_(C≤8), aralkoxy_(C≤8), heteroaryloxy_(C≤8), acyloxy_(C≤8),
 heterocycloalkoxy_(C≤8), alkylamino_(C≤8), dialkylamino_(C≤8),
 alkenylamino_(C≤8), alkoxyamino_(C≤8), arylamino_(C≤8),
 aralkylamino_(C≤8), heteroarylamino_(C≤8), heterocyclo-
 alkylamino_(C≤8), alkylsulfonylamino_(C≤8), amido_(C≤8),
 $-\text{NH}-\text{amido}_{(C≤8)}$, or a substituted version of any of these
 groups;


or a pharmaceutically acceptable salt thereof.


5. The compound according to any one of claims 1-4, wherein the bond between carbon atoms a and b is a single bond.
6. The compound according to any one of claims 1-4, wherein the bond between carbon atoms a and b is a double bond.


7. The compound according to any one of claims 1, 3 and 5-6, wherein Y is a covalent bond.
8. The compound according to any one of claims 1-6, wherein Y is $-\text{CH}_2-$.
9. The compound according to any one of claims 1-6, wherein Y is $-\text{C}(\text{O})-$.
- 5 10. The compound according to any one of claims 1-6, wherein Y is $-\text{O}-$.
11. The compound according to any one of claims 1 and 5-10, wherein R_1 is $-\text{H}$.
12. The compound according to any one of claims 1 and 5-10, wherein R_2 is methyl.
13. The compound according to any one of claims 1-12, wherein R_3 is $-\text{H}$.
14. The compound according to any one of claims 1-12, wherein R_3 is $-\text{OH}$.
- 10 15. The compound according to any one of claims 1-12, wherein R_3 is amino.
16. The compound according to any one of claims 1-12, wherein R_3 is $\text{alkyl}_{(\text{C}\leq 8)}$.
17. The compound of claim 16, wherein R_3 is methyl.
18. The compound according to any one of claims 1-12, wherein R_3 is heterocycloalkyl $_{(\text{C}\leq 8)}$.
- 15 19. The compound of claim 18, wherein R_3 is morpholinyl, pyrrolidinyl, azetidinyll or piperazinyl.
20. The compound according to any one of claims 1-12, wherein R_3 is substituted heterocycloalkyl $_{(\text{C}\leq 8)}$.
21. The compound of claim 20, wherein R_3 is hydroxypyrrolidinyl, difluoropyrrolidinyl, 20 hydroxypiperidinyl, or *N*-Boc-piperazinyl.
22. The compound according to any one of claims 1-12, wherein R_3 is acyl $_{(\text{C}\leq 8)}$.
23. The compound of claim 22, wherein R_3 is acetyl.


24. The compound according to any one of claims 1-12, wherein R_3 is substituted acyl_(C≤8).
25. The compound of claim 24, wherein R_3 is ethylaminocarbonyl.
26. The compound according to any one of claims 1-12, wherein R_3 is alkoxy_(C≤8).
- 5 27. The compound of claim 16, wherein R_3 is methoxy, ethoxy, isopropoxy, *tert*-butoxy, or $-O-$ cyclohexyl.
28. The compound according to any one of claims 1-12, wherein R_3 is aryloxy_(C≤8).
29. The compound of claim 28, wherein R_3 is $-O-$ phenyl.
30. The compound according to any one of claims 1-12, wherein R_3 is aralkoxy_(C≤8).
- 10 31. The compound of claim 30, wherein R_3 is benzyloxy.
32. The compound according to any one of claims 1-12, wherein R_3 is substituted acyloxy_(C≤8).
33. The compound of claim 32, wherein R_3 is $-OC(O)NHCH_2CH_3$.
34. The compound according to any one of claims 1-12, wherein R_3 is
15 heterocycloalkoxy_(C≤8).
35. The compound of claim 34, wherein R_3 is $-O-$ piperidinyl or *N*-Boc-piperidinyl.
36. The compound according to any one of claims 1-12, wherein R_3 is alkylamino_(C≤8).
37. The compound of claim 36, wherein R_3 is methylamino, ethylamino, isopropylamino, *tert*-butylamino or cyclohexylamino.
- 20 38. The compound according to any one of claims 1-12, wherein R_3 is substituted alkylamino_(C≤8).
39. The compound of claim 38, wherein R_3 is 2,2,2-trifluoroethylamino, $-NHCH_2C(O)OCH_3$ or $-NHCH_2C(O)OH$.
40. The compound according to any one of claims 1-12, wherein R_3 is dialkylamino_(C≤8).


41. The compound of claim 40, wherein R_3 is dimethylamino.
42. The compound according to any one of claims 1-12, wherein R_3 is alkoxyamino_(C≤8).
43. The compound of claim 42, wherein R_3 is methoxyamino.
44. The compound according to any one of claims 1-12, wherein R_3 is arylamino_(C≤8).
- 5 45. The compound of claim 44, wherein R_3 is phenylamino.
46. The compound according to any one of claims 1-12, wherein R_3 is aralkylamino_(C≤8).
47. The compound of claim 46, wherein R_3 is benzylamino.
48. The compound according to any one of claims 1-12, wherein R_3 is heteroarylamino_(C≤8).
- 10 49. The compound of claim 48, wherein R_3 is pyridinylamino.
50. The compound according to any one of claims 1-12, wherein R_3 is heterocycloalkylamino_(C≤8).
51. The compound of claim 50, wherein R_3 is oxetanylamino.
52. The compound according to any one of claims 1-12, wherein R_3 is -NH-amido_(C≤8).
- 15 53. The compound of claim 52, wherein R_3 is -NHNHC(O)CH₃.
54. The compound of claim 1, further defined as:












or a pharmaceutically acceptable salt thereof.

55. A compound of the formula:



5 wherein:

n is 1 to 6;

R_1 and R_2 are each independently $-H$, $-OH$, methyl, or as defined below; and

R_3 is:


amino or $-NHOH$; or

10 N -heteroaryl_(C≤8), N -heterocycloalkyl_(C≤8), alkylamino_(C≤8),
dialkylamino_(C≤8), alkenylamino_(C≤8), alkoxyamino_(C≤8),
arylamino_(C≤8), aralkylamino_(C≤8), heteroarylamino_(C≤8),
heterocycloalkylamino_(C≤8), alkylsulfonylamino_(C≤8), amido_(C≤8),
15 $-NH$ -amido_(C≤8), or a substituted version of any of these
groups;

R_3 and R_1 , taken together, are $-NR_a-$, wherein R_a is hydrogen or
alkyl_(C≤4); or

R_3 and R_2 , taken together, are $-NR_a-$, wherein R_a is hydrogen or alkyl_(C≤4); or
or a pharmaceutically acceptable salt thereof.

56. The compound of claim 55, further defined as:



wherein:

n is 1 to 6; and

R_3 is:

amino or $-NHOH$; or

10 N -heteroaryl_(C≤8), N -heterocycloalkyl_(C≤8), alkylamino_(C≤8),
dialkylamino_(C≤8), alkenylamino_(C≤8), alkoxyamino_(C≤8),
arylamino_(C≤8), aralkylamino_(C≤8), heteroarylamino_(C≤8),
heterocycloalkylamino_(C≤8), alkylsulfonylamino_(C≤8), amido_(C≤8),
15 $-NH$ -amido_(C≤8), or a substituted version of any of these
groups;

or a pharmaceutically acceptable salt thereof.


57. The compound according to either one of claim 55 and 56, wherein n is 1.

58. The compound according to either one of claim 55 and 56, wherein n is 2.

59. The compound according to either one of claim 55 and 56, wherein n is 3.

20 60. The compound according to any one of claims 55 and 57-59, wherein R_1 is $-H$.

61. The compound according to any one of claims 55 and 57-59, wherein R_2 is methyl.
62. The compound according to any one of claims 55-61, wherein R_3 is *N*-heteroaryl_(C≤8).
63. The compound of claim 62, wherein R_3 is imidazolyl.
64. The compound according to any one of claims 55-61, wherein R_3 is
 5 *N*-heterocycloalkyl_(C≤8).
65. The compound of claim 64, wherein R_3 is morpholinyl or pyrrolidinyl.
66. The compound according to any one of claims 55-61, wherein R_3 is alkylamino_(C≤8).
67. The compound of claim 66, wherein R_3 is ethylamino.
68. The compound of claim 55, further defined as:



69. A pharmaceutical composition comprising:

- 15 a) the compound according to any one of claims 1-68; and

b) an excipient.

70. A method of treating and/or preventing a disease or a disorder in a patient in need thereof, comprising administering to the patient a compound according to any one of claims 1-68 in an amount sufficient to treat and/or prevent the disease or disorder.

5